Treatment of muscle tension disorders
Inhibiting calcium channels with calcium channel blockers like verapamil addresses the lack of effective treatments for myotonic disorders, improving muscle function and survival by reducing muscle tone and enhancing respiratory capabilities.
Patent Information
- Application Number
- JP2024527370
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-02
- Filing Date
- 2022-11-10
- Publication Date
- 2024-12-03
AI Technical Summary
Myotonic disorders, such as myotonic dystrophy, lack effective treatments, leading to progressive disability and significant quality of life deterioration due to muscle tone issues, muscle weakness, and other systemic complications.
Administering calcium channel blockers, such as verapamil, amlodipine, or diltiazem, to inhibit calcium channels in muscle cells, reducing muscle tone and improving muscle function and survival in subjects with myotonic disorders.
The treatment significantly improves muscle tone, muscle function, righting reflex time, respiratory function, and diaphragm strength, leading to at least a 50% improvement compared to untreated subjects, and extends survival in affected individuals.
Smart Images

Figure 2024544519000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 63 / 277,816, filed November 10, 2021, and U.S. Provisional Patent Application No. 63 / 374,378, filed September 2, 2022. The foregoing applications are hereby incorporated by reference in their entireties.
[0002] Statement Regarding Federally Sponsored Research This invention was made with Government support under UL1TR002001 awarded by the National Institutes of Health. The Government has certain rights in this invention.
[0003] The present invention relates to methods and medicaments for the treatment of myotonic disorders. [Background technology]
[0004] Myotonic disorders are a group of inherited diseases characterized by the presence of muscle tone, defined as impaired muscle relaxation after activation. The presentation of these disorders may range from asymptomatic electrical muscle tone, as seen in some forms of congenital myotonia (MC), to severe disorders with muscle weakness, cardiac conduction defects, and other systemic features, such as myotonic dystrophy type I (DM1). DM1, the most common form of muscular dystrophy in adults, is estimated to affect more than 100,000 people in the United States, many of whom experience decades of progressive disability, with a median survival of 55 years. Due to the debilitating and progressive nature of these disorders, including myotonic dystrophy, the resulting disability and loss of quality of life for patients, the significant cost of supportive care, and the lack of a definitive cure, new and effective means of treating myotonic disorders are urgently needed. Summary of the Invention
[0005] The present disclosure addresses the above needs in several aspects. In one aspect, the present disclosure provides a method of treating a myotonic disorder in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an agent that inhibits calcium channels in the subject's cells (e.g., a calcium channel blocker, such as a use-dependent calcium channel blocker). In some embodiments, the agent comprises a calcium channel blocker, a stereoisomer thereof, a derivative thereof, or a pharma- ceutically acceptable salt thereof, or a combination thereof.
[0006] In some embodiments, the calcium channel is a Cav1.1 calcium channel. In some embodiments, the subject is a mammal, for example a human.
[0007] In some embodiments, the agent is selected from verapamil, amlodipine, diltiazem, nifedipine, stereoisomers, derivatives thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
[0008] In some embodiments, the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia. In some embodiments, the myotonic dystrophy is myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2). In some embodiments, the myotonic dystrophy is associated with abnormal alternative splicing of RNA encoding the CIC-1 chloride channel or the Cav1.1 calcium channel. In some embodiments, the congenital myotonia is Becker type or Thomsen type congenital myotonia. In some embodiments, the sodium channel myotonia is paramyotonia congenita, hyperkalemic periodic paralysis, or potassium-induced myotonia. In some embodiments, the subject has one or more mutations in SCN4A, Clcn1, or Cac1ns. In some embodiments, the subject has alternative splice isoforms of Clcn1 or Cac1ns.
[0009] In some embodiments, the agent is administered to the subject in one or more doses of about 0.01 to about 100 mg / kg of the subject's body weight. In some embodiments, the agent is administered in one or more doses of about 1 to about 50 mg / kg of the subject's body weight. In some embodiments, the agent is administered in one or more doses of about 8 to about 16 mg / kg of the subject's body weight.
[0010] In some embodiments, one or more doses of the agent are administered at least every 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, or 4 weeks.
[0011] In some embodiments, the agent is administered to the subject intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, sublingually, sustained release, controlled release, delayed release, or as a suppository.
[0012] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent or therapy. In some embodiments, the additional therapeutic agent is selected from ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, lamotrigine, and combinations thereof. In some embodiments, the additional therapeutic agent or therapy is administered to the subject before, after, or simultaneously with the agent.
[0013] In some embodiments, the treatment results in a therapeutic effect selected from reduced muscle tone, reduced weight loss, improved survival, improved muscle function, improved righting time, improved respiratory function, and improved diaphragm strength, hi some embodiments, the treatment results in at least a 50% improvement in muscle tone, weight loss, survival, muscle function, righting time, respiratory function, or diaphragm strength compared to untreated subjects.
[0014] In another aspect, the present disclosure also provides the use of an agent that inhibits calcium channels in the manufacture of a medicament for treating myotonic disorder in a subject in need thereof.In some embodiments, the agent is selected from verapamil, amlodipine, diltiazem, nifedipine, their stereoisomers, their derivatives, or their pharma- ceutically acceptable salts, and combinations thereof.In some embodiments, the calcium channel is a Cav1.1 calcium channel.In some embodiments, the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia.
[0015] In yet another aspect, the disclosure further provides pharmaceutical compositions for treating, for example, myotonic disorders in a subject in need thereof. In some embodiments, the pharmaceutical compositions include (a) a calcium channel blocker selected from verapamil, amlodipine, diltiazem, nifedipine, and combinations thereof, and (b) one or more agents selected from ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, and lamotrigine.
[0016] Also within the scope of this disclosure are kits that contain the pharmaceutical compositions described herein.
[0017] The details of one or more embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and the claims.
[0018] The above summary is not intended to define all aspects of the disclosure, and additional aspects are described in other sections, such as the following detailed description. It should be understood that the entire specification is intended to relate as a unified disclosure, and that all combinations of features described herein are contemplated, even if the combinations of features are not found together in the same sentence, paragraph, or section of the specification. Other features and advantages of the present invention will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while showing specific embodiments of the disclosure, are given for illustrative purposes only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]
[0019] [Fig. 1A-1F] A series of graphs showing that CaV1.1Δe29 and ClC-1- / - alleles are synthetically lethal, resulting in significant weight loss and severe muscle weakness in mice. Figure 1A shows the results of Kaplan-Meier survival analysis of WT (n=10), Cav1.1Δe29 / + (n=13), Cav1.1Δe29 (n=15), ClC-1- / - (n=40), Cav1.1Δe29 / + / ClC-1- / - (n=16), and Cav1.1Δe29 / Δe29 / ClC-1- / - (n=21). Figure 1B shows the results of weekly weight analysis. Figure 1C shows the percentage weight change from weaning at 10 weeks. Figure ID shows representative specific force traces, and Figure IE shows the average peak specific force evoked by 150 Hz (500 ms) tetanic stimulation of isolated EDL muscles from 10-week-old mice. Figure IF shows the average frequency-dependence of specific force generation evoked from isolated EDL muscles from 10-week-old mice. Symbols, open circles, individual mice; bars and filled circles, mean ± SEM. [Fig. 2A-2F]A series of graphs showing that verapamil treatment improves survival, body weight, and muscle function in Cav1.1Δe29 / ClC-1− / − mice. FIG. 2A shows the results of Kaplan-Meier survival analysis of WT+vehicle (n=10), WT+200 mg / kg / day verapamil (n=10), Cav1.1Δe29 / ClC-1− / − (n=37), and Cav1.1Δe29 / Δe29 / ClC-1− / −+verapamil (n=9). Verapamil is administered in the nutrition / hydration food cup of the mice. FIG. 2B shows the results of the body weight analysis. FIG. 2C and 2E show representative specific force traces evoked by twitch (left) and 150 Hz (500 ms) tetanic (right) stimulation of EDL muscles isolated from 10-week (FIG. 2C) and 20-week (FIG. 2E) mice. Figures 2D and 2F show plots of the mean stimulation frequency dependence of specific force production from isolated EDL muscles at 10 weeks of age (Figure 2D) and 20 weeks of age (Figure 2F) in the indicated genotypes and treatment groups. Symbols, filled circles, mean ± SEM. [Figure 3A-3C] FIG. 3 is a series of graphs showing that verapamil treatment significantly improves righting time in ClC-1- / - and Cav1.1Δe29 / ClC-1- / - mice. FIG. 3A shows the results of weekly righting time analysis of Cav1.1Δe29 / ClC-1- / -, ClC-1- / -, Cav1.1Δe29, WT, Cav1.1Δe29 / ClC-1- / -+verapamil, and WT+verapamil mice, and FIG. 3B shows the average righting time in vehicle- and verapamil-treated mice at 10 and 20 weeks of age. Untreated Cav1.1Δe29 / ClC-1- / - mice do not survive to 20 weeks of age, so the last recording before death is documented. Boxes denote Q1, median, and Q3, and whiskers indicate minimum and maximum values. Figure 3C shows pairs of ClC-1- / - mice before (light circles) and after (dark circles) 2 weeks of verapamil treatment at doses of 100 mg / kg / day (left) and 200 mg / kg / day (right) in nutrition / hydration food cups. Symbols, filled circles, individual mice; open circles, mean ± SEM. [Figure 4A-4G]
[0036] Figure 4 is a series of graphs showing that verapamil treatment significantly improves respiratory function and diaphragm strength in Cav1.1Δe29 / ClC-1- / - mice. Whole-body plethysmography of 10-week-old (Figures 4A and 4C) and 20-week-old (Figures 4B and 4D) mice of the indicated genotypes and treatment groups. Figures 4A and 4B show respiratory frequency (breaths / min), and Figures 4C and 4D show respiratory ventilation (mL). Figure 4E shows representative tetanic (150 Hz, 500 ms) specific force traces from diaphragm strips isolated from 10-week-old (left) and 20-week-old (right) mice of the indicated genotypes and treatment groups. Figures 4F and 4G show plots of the mean stimulation frequency dependence of specific force generated from diaphragm strips isolated from 10-week-old (Figure 4F) and 20-week-old (Figure 4G) mice of the indicated genotypes and treatment groups. Symbols, open circles, individual mice; bars and closed circles, mean ± SEM. Note: Untreated Cav1.1Δe29 / ClC-1− / − mice do not survive to 20 weeks of age. [Figure 5A-5D] 5A and 5C are a series of graphs showing that Cav1.1Δe29 / ClC-1− / − muscles show severe transient weakness that is significantly ameliorated by the addition of verapamil. Figures 5A and 5C show representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms), spaced 4 s apart, recorded ex vivo from isolated EDLs from 6-week-old ClC-1− / − and Cav1.1Δe29 / ClC-1− / − mice in the absence of verapamil (FIG. 5A) and in the presence of 20 μM verapamil added to the bath (FIG. 5C). Figures 5B and 5D show plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from each other in the absence of verapamil (Figure 5B) and ClC-1- / - (n=4), Cav1.1Δe29 (n=4), and Cav1.1Δe29 / ClC-1- / -, n=4) mice at 6 weeks in the absence of verapamil (Figure 5B) and in the presence of 20 μM verapamil added to the bath (Figure 5D). The dashed line in Figure 5D represents the average data presented in Figure 5B as a pre-treatment reference. Symbols, filled circles, mean ± SEM. [Figures 6A-6H]6A and 6C show representative normalized specific force traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) from EDLs isolated from 6-week-old WT and Cav1.1Δe29 mice in the absence of verapamil (FIG. 6A) and in the presence of 20 mM verapamil added to the bath (FIG. 6C). The dashed lines represent the accumulated force. FIG. 6B and 6D show the average normalized integral of force of WT and Cav1.1Δe29 EDLs over three tetanic stimuli (150 Hz, 500 ms) in the absence of verapamil (FIG. 6B) and in the presence of 20 mM verapamil added to the bath (FIG. 6D). Figures 6E and 6G show representative normalized specific force traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) from EDLs isolated from 6-week-old ClC-1- / - and Cav1.1Δe29 / ClC-1- / - mice in the absence (Figure 6E) and presence (Figure 6G) of 20 mM verapamil added to the bath. The dashed lines represent the accumulated forces. Figures 6F and 6H show the mean integral of force of ClC-1- / - and Cav1.1Δe29 / ClC-1- / - EDLs over three tetanic stimuli (150 Hz, 500 ms) in the absence (Figure 6B) and presence (Figure 6D) of 20 mM verapamil added to the bath. Symbols, open circles, individual mice; bars, mean ± SEM. Contralateral EDLs were used for each untreated and treated experiment. All traces were plotted on the same time scale and normalized force for comparison. [Figure 7A-7B]
[0036] Figure 7 is a series of graphs showing that chronic oral verapamil feeding of Cav1.1Δe29 / ClC-1- / - mice significantly rescues EDL muscle force production. Mean peak specific force evoked using 150 Hz (500 ms) tetanic stimulation of isolated EDL from 10 week (Figure 7A) and 20 week (Figure 7B) mice of the indicated genotypes and treatments. Symbols, open circles, individual mice; bars, mean ± SEM. [Figure 8A-8B]
[0036] Figure 8 is a series of graphs showing that chronic oral verapamil feeding of Cav1.1Δe29 / ClC-1- / - mice significantly rescues diaphragm muscle force production. Mean peak specific force evoked using 150 Hz (500 ms) tetanic stimulation of diaphragm strips isolated from 10-week (Figure 8A) and 20-week (Figure 8B) mice of the indicated genotypes and treatments. Symbols, open circles, individual mice; bars, mean ± SEM. [Figure 9A-9D] 9A-9D are a series of graphs showing the results of quantification and statistical analysis of fiber type distribution in the tibialis anterior muscle. Quantification of type IIb (FIG. 9A), type IIx (FIG. 9B), type IIa (FIG. 9C), and type I (FIG. 9D) fibers in the tibialis anterior muscle at 10 weeks (left) and 20 weeks (right) (n=5 / group) is shown. [Figure 10A-10D] 10A-10D are a series of graphs showing the results of quantification and statistical analysis of fiber type distribution in diaphragm muscle. Quantification of type IIb (FIG. 10A), type IIx (FIG. 10B), type IIa (FIG. 10C), and type I (FIG. 10D) fibers in diaphragm muscles at 10 weeks (left) and 20 weeks (right) (n=5 / group) is shown. [Figures 11A-11C] A series of figures showing that heterozygous and homozygous Cav1.1Δe29 mice show similar Cav1.1 voltage dependence and peak current density in flexor digitorum brevis muscle. Figure 11A shows representative current density traces from whole-cell patch clamp of flexor digitorum brevis muscle fibers isolated from 4-week WT, Cav1.1Δe29 / + (dashed line), and Cav1.1Δe29 / Δe29 (solid line) mice at 0 mV (top), +20 mV (middle), and +40 mV (bottom). Figure 11B shows plots of the average current-voltage relationship of Cav1.1 activity measured in WT, Cav1.1Δe29 / + (circles, dashed line), and Cav1.1Δe29 / Δe29 (circles, solid line) flexor digitorum brevis muscle fibers isolated from 4-week mice. Figure 11C shows RT-PCR products of Cav1.1 RNA isolated from tibialis anterior muscles from 10-week-old mice. PCR amplification is from exons 27 to 31 of the Caca1ns cDNA. [Figure 12A-12D]12A and 12C are a series of graphs (not normalized to the first peak force) showing severe transient weakness in Cav1.1Δe29 / ClC-1− / − muscles that is significantly ameliorated by the addition of verapamil. Figures 12A and 12C show representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms), spaced 4 s apart, recorded ex vivo from EDLs isolated from 6-week-old ClC-1− / − and Cav1.1Δe29 / ClC-1− / − mice in the absence of verapamil (Figure 12A) and in the presence of 20 μM verapamil added to the bath (Figure 12C). Figures 12B and 12D show plots of the average peak tetanic EDL evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from each other from 6-week WT (n=4), ClC-1- / - (n=4), Cav1.1Δe29 (n=4), and Cav1.1Δe29 / ClC-1- / -, n=4) mice in the absence of verapamil (Figure 12B) and in the presence of 20 μM verapamil added to the bath (Figure 12D). The dashed line in Figure 12D represents the average data presented in Figure 12B as a pre-treatment reference. Symbols, filled circles, mean ± SEM. [Fig. 13A-13H]
[0036] Figure 13A, 13C, 13E, and 13G show representative traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL of WT (Figure 13A), Cav1.1Δe29 (Figure 13C), ClC-1- / - (Figure 13E), and Cav1.1Δe29 / ClC-1- / - (Figure 13G) in the absence of verapamil and in the presence of 20 mM verapamil. Treatments are indicated in the legend. Figures 13B, 13D, 13F, and 13H show the average specific force of the EDL of WT (Figure 13B), Cav1.1Δe29 (Figure 13D), ClC-1- / - (Figure 13F), and Cav1.1Δe29 / ClC-1- / - (Figure 13H) over three tetanic stimulations in the absence and presence of 20 mM verapamil. Treatments are indicated in the legend. Symbols, open circles, individual mice; bars, mean and SEM. [Figure 14A-14B] 14A-14C are a series of graphs showing that verapamil significantly reduces muscle tone in both Cav1.1Δe29 / ClC-1- / - and ClC-1- / - mouse muscles. FIG. 14A shows representative traces of normalized specific force production of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL of ClC-1- / - (solid line) and Cav1.1Δe29 / ClC-1- / - (solid line) in the absence of 20 μM verapamil. The dashed line represents the accumulated force. FIG. 14B shows representative traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL of ClC-1- / - (solid line) and Cav1.1Δe29 / ClC-1- / - (solid line) in the presence of 20 μM verapamil. The dashed line represents the accumulated force. NOTE: The traces shown in Figure 6 are replotted here on an expanded time scale to better observe the muscle tone. [Fig. 15A-15F]A series of graphs showing that Cav1.1Δe29 exacerbates transient weakness in myotonic muscles and is alleviated by verapamil. Figure 15A shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC added to the bath (pre-treatment). Figure 15B shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from WT (n=5), WT+9-AC (n=5), Cav1.1Δe29 (n=5), and Cav1.1Δe29+9-AC (n=5) mice. Figures 15C and 15E show representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms), spaced 4 s apart, recorded ex vivo from isolated EDLs from 20-week WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC and 5 mM verapamil (Figure 15C) or 20 mM verapamil (Figure 15E) added to the bath. FIG. 15D shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from the EDLs of WT + 5 mM verapamil (n=5), WT + 9-AC + 5 mM verapamil (n=5), Cav1.1Δe29 + 5 mM verapamil (n=5), and Cav1.1Δe29 + 9-AC + 5 mM verapamil (n=5). FIG. 15F shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from EDLs of WT+20 mM verapamil (n=5), WT+9-AC+20 mM verapamil (n=5), Cav1.1Δe29+20 mM verapamil (n=5), and Cav1.1Δe29 + 9-AC+20 mM verapamil (n=5). The dashed lines in FIG. 15D and 15F represent the average data presented in FIG. 15B as a pretreatment reference. Symbols, filled circles, mean±SEM. Note: When possible, the contralateral EDL was used. [Figure 16A-16B]16A-B are a series of graphs showing that transient weakness is absent in WT and Cav1.1Δe29 muscles. FIG. 16 shows representative traces of the first 15 tetanic contractions (150 Hz, 500 ms) spaced 4 s apart in 20-week WT and Cav1.1Δe29 EDL muscles. FIG. 16B shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from EDLs isolated from 20-week WT and Cav1.1Δe29 mice. Symbols, filled circles, mean ± SEM. [Fig. 17A-17F] A series of graphs showing that Cav1.1Δe29 significantly worsens muscle tone. Figures 17A, 17B, and 17C (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from isolated EDLs from 20-week WT and Cav1.1Δe29 mice in the absence (pre-treatment) of verapamil (Figure 17A, left) and in the presence (pre-treatment) of 5 mM (Figure 17B, left) and 20 mM (Figure 17C, left) verapamil added to the bath. The dashed lines represent the accumulated force production. Figures 17A, 17B, and 17C (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 17D, 17E, and 17F (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms), 3 min apart, recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice incubated with 100 mM 9-AC in the absence (pre-treatment) of verapamil (Figure 17D, left) and in the presence (pre-treatment) of 5 mM (Figure 17E, left) and 20 mM (Figure 17F, left) verapamil added to the bath. The dashed line represents the accumulated force production. Figures 17D, 17E, and 17F (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used. [Fig. 18A-18F]18A-C are a series of graphs showing that verapamil treatment does not reduce peak contractile force in non-myotonic and myotonic WT and Cav1.1Δe29 mouse muscles. Representative specific force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from isolated EDLs from 20-week WT and Cav1.1Δe29 mice in the absence (pre-treatment) of verapamil (FIG. 18A, left) and in the presence (pre-treatment) of 5 mM (FIG. 18B, left) and 20 mM (FIG. 18C, left) verapamil added to the bath. The dashed lines represent the accumulated force production. FIGS. 18A, 18B, and 18C (right) show plots of the average integral of the specific force shown in the respective left panels. Figures 18D, 18E, and 18F (left) show representative specific force traces of the first of three tetanic contractions (100 Hz, 500 ms), 3 min apart, recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice incubated with 100 mM 9-AC and in the absence (pre-treatment) of verapamil (Figure 18D, left) and in the presence (pre-treatment) of 5 mM (Figure 18E, left) and 20 mM (Figure 18F, left) verapamil added to the bath. The dashed line represents the accumulated force production. Figures 18D, 18E, and 18F (right) show plots of the average integral of the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used. [Figure 19A-19B] A series of graphs showing that CaV1.1De29 and ClC-1- / - alleles are synthetically lethal, resulting in significant weight loss and severe muscle weakness in mice. Amlodipine treatment significantly improved survival and weight change rate. Figure 19A shows the results of Kaplan-Meier survival analysis of WT (n=10), Cav1.1Δe29 / + (n=13), Cav1.1Δe29 (n=15), ClC-1- / - (n=40), Cav1.1Δe29 / + / ClC-1- / - (n=16), Cav1.1Δe29 / Δe29 / ClC-1- / - (n=21), and Cav1.1Δe29 / ClC-1- / - + 5 mg / kg / day amlodipine (n=6). Figure 19B shows the weight change rate from weaning at 10 weeks. Symbols, open circles, individual mice; bars and closed circles, mean ± SEM. [Figure 20A-20B] FIG. 20 is a series of graphs showing that amlodipine treatment significantly improves righting time in Cav1.1Δe29 / ClC-1− / − mice compared to untreated. FIG. 20A shows weekly righting time analysis of Cav1.1Δe29 / ClC-1− / −, ClC-1− / −, Cav1.1Δe29, WT, Cav1.1Δe29 / ClC-1− / − + amlodipine (purple) mice. FIG. 20B shows the average righting time in vehicle and amlodipine treated mice at 10 and 20 weeks of age. Note: Untreated Cav1.1Δe29 / ClC-1− / − mice do not survive to 20 weeks of age, so the last recording before death is documented. Boxes denote Q1, median, and Q3; whiskers indicate minimum and maximum values. Symbols, filled circles, individual mice; open circles, mean ± SEM. [Figures 21A-21C] FIG. 21 is a series of graphs showing that Cav1.1Δe29 / ClC-1− / − mice exhibit altered breathing compared to WT, and that Cav1.1Δe29 / ClC-1− / − mice treated with amlodipine do not have significantly different frequency or minute ventilation compared to WT. Whole-body plethysmography of 10-week (left) and 20-week (right) mice of the indicated genotypes and treatment groups. Respiratory frequency (breaths / min) (FIG. 21A), respiratory ventilation (mL) (FIG. 21B), and minute ventilation (FIG. 21C) are shown. Symbols, open circles, individual mice; bars and filled circles, mean ± SEM. Note: Untreated Cav1.1Δe29 / ClC-1− / − mice do not survive to 20 weeks of age. [Fig. 22A-22B]22A-C are a series of graphs showing that EDLs isolated from Cav1.1Δe29 / ClC-1− / − mice treated with amlodipine have muscle function similar to untreated ClC-1− / − mice. FIG. 22A shows representative specific force traces elicited by 150 Hz (500 ms) tetanic (right) stimulation of EDL muscles isolated from 20-week-old mice. FIG. 22B shows the average tetanic force generated during 500 ms, 150 Hz tetanic stimulation in EDL muscles isolated from 20-week-old mice. FIG. 22C shows plots of the average stimulation frequency dependence of specific force generation from isolated EDL muscles at 20 weeks of age in the indicated genotypes and treatment groups. Symbols, filled circles, mean ± SEM. [Figures 23A-23C] 23A-23C are a series of graphs showing that amlodipine treatment improves muscle function and reduces force production in diaphragm strips isolated from amlodipine-treated Cav1.1Δe29 / ClC-1− / − mice compared to WT diaphragms. FIG. 23A shows representative specific force traces evoked by 150 Hz (500 ms) tetanic (right) stimulation of diaphragm strips isolated from 20-week-old mice. FIG. 23B shows the average tetanic force generated during 500 ms, 150 Hz tetanic stimulation in diaphragm strips isolated from 20-week-old mice. FIG. 23C shows plots of the average stimulation frequency dependence of specific force generation from isolated diaphragm strips at 20 weeks of age in the indicated genotypes and treatment groups. Symbols, filled circles, mean ± SEM. [Fig. 24A-24D]24A-24B are a series of graphs showing that Cav1.1Δe29 exacerbates transient weakness in myotonic muscles and is alleviated by amlodipine. Figure 24A shows representative normalized force traces of the first 15 tetanic contractions (100Hz, 500ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the presence of 100mM 9-AC added to the bath (before treatment). Figure 24B shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100Hz, 500ms tetanic stimuli spaced 4 seconds apart from WT (n=5), WT+9-AC (n=5), Cav1.1Δe29 (n=5), and Cav1.1Δe29+9-AC (n=5) mice. Figure 24C shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week-old WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC and 10 mM amlodipine (Figure 24C) added to the bath. Figure 24D shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from WT+10 mM amlodipine (n=5), WT+9-AC+10 mM amlodipine (n=5), Cav1.1Δe29+10 mM amlodipine (n=5), and Cav1.1Δe29 + 9-AC+10 mM amlodipine (n=5) EDLs. The dashed line in Figure 24D represents the average data presented in Figure 24B as a pre-treatment reference. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used. [Fig. 25A-25D]A series of graphs showing that Cav1.1Δe29 exacerbates transient weakness in myotonic muscles and is alleviated by diltiazem. Figure 25A shows representative normalized force traces of the first 15 tetanic contractions (100Hz, 500ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the presence of 100mM 9-AC added to the bath (pre-treatment). Figure 25B shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100Hz, 500ms tetanic stimuli spaced 4 seconds apart from WT (n=5), WT+9-AC (n=5), Cav1.1Δe29 (n=5), and Cav1.1Δe29+9-AC (n=5) mice. Figure 25C shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week-old WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC and 10 mM diltiazem added to the bath (Figure 25C). Figure 25D shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from WT+10 mM diltiazem (n=5), WT+9-AC+10 mM diltiazem (n=5), Cav1.1Δe29+10 mM diltiazem (n=5), and Cav1.1Δe29+9-AC+10 mM diltiazem (n=5) EDLs. The dashed line in (FIG. 25D) represents the average data presented in (FIG. 25B) as a pre-treatment reference. Symbols, filled circles, mean±SEM. Note: When possible, the contralateral EDL was used. [Figures 26A-26D]A series of graphs showing that Cav1.1Δe29 exacerbates transient weakness in myotonic muscles and is alleviated by nifedipine. Figure 26A shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC added to the bath (pre-treatment). Figure 26B shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from WT (n=5), WT+9-AC (n=5), Cav1.1Δe29 (n=5), and Cav1.1Δe29+9-AC (n=5) mice. Figure 26C shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the presence of 100 mM 9-AC and 10 mM nifedipine (Figure 26C) added to the bath. Figure 26D shows plots of the average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from WT+10 mM nifedipine (n=5), WT+9-AC+10 mM nifedipine (n=5), Cav1.1Δe29+10 mM nifedipine (n=5), and Cav1.1Δe29 + 9-AC+10 mM nifedipine (n=5) EDLs. The dashed line in Figure 26D represents the average data presented in Figure 26B as a pre-treatment reference. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used. [Figure 27A-27B]27A-B are a series of graphs showing that transient weakness is absent in WT and Cav1.1Δe29 muscles. Figure 27A shows representative traces of the first 15 tetanic contractions (150 Hz, 500 ms) spaced 4 seconds apart in 20-week WT and Cav1.1Δe29 EDL muscles. Figure 27B shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from EDLs isolated from 20-week WT and Cav1.1Δe29 mice. Symbols, filled circles, mean ± SEM. [Fig. 28A-28D] A series of graphs showing that Cav1.1Δe29 significantly worsened muscle tone and amlodipine reduced muscle tone in myotonic WT and Cav1.1Δe29 EDLs. Figures 28A and 28B (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the absence (pre-treatment) of amlodipine (Figure 28A, left) and in the presence of 10 mM amlodipine added to the bath (Figure 28B, left). The dashed lines represent the accumulated force production. Figures 28A and 28B (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 28C and 28D (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms), 3 min apart, recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice incubated with 100 mM 9-AC in the absence (pre-treatment) of amlodipine (Figure 28C, left) and in the presence of 10 mM amlodipine added to the bath (Figure 28D, left). The dashed line represents the accumulated force production. Figures 28C and 28D (right) show plots of the mean integral normalized against the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used. [Figures 29A-29D]A series of graphs showing that Cav1.1Δe29 significantly worsened muscle tone and diltiazem reduced muscle tone in myotonic WT and Cav1.1Δe29 EDLs. Figures 29A and 29B (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the absence (pre-treatment) of diltiazem (Figure 29A, left) and in the presence of 10 mM diltiazem added to the bath (Figure 29B, left). The dashed lines represent the accumulated force production. Figures 29A and 29B (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 29C and 29D (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms), 3 min apart, recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice incubated with 100 mM 9-AC in the absence (pre-treatment) of diltiazem (Figure 29C, left) and in the presence of 10 mM diltiazem added to the bath (Figure 29D, left). The dashed line represents the accumulated force production. Figures 29C and 29D, right, show plots of the average integral normalized to the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used. [Fig. 30A-30D]A series of graphs showing that Cav1.1Δe29 significantly worsened muscle tone and nifedipine reduced muscle tone in myotonic WT and Cav1.1Δe29 EDLs. Figures 30A and 30B (left) Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice in the absence (pre-treatment) of nifedipine (Figure 30A, left) and in the presence of 75 nM nifedipine added to the bath (Figure 30B, left). The dashed lines represent the accumulated force production. Figures 30A and 30B (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 30C and 30D (left) show representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms), 3 min apart, recorded ex vivo from EDLs isolated from 20-week WT and Cav1.1Δe29 mice incubated with 100 mM 9-AC in the absence (pre-treatment) of nifedipine (Figure 30C, left) and in the presence of 75 nM nifedipine added to the bath (Figure 30D, left). The dashed line represents the accumulated force production. Figures 30C and 30D (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used. [Figure 31A-31C]A series of graphs showing that the combination of HSALR and Mbnl1- / - is synthetically lethal, resulting in significant reductions in survival and body weight, and prolonged time to positive. Figure 31A shows the results of Kaplan-Meier survival analysis of HSALR / Mbnl1+ / + +vehicle, HSALR / Mbnl1+ / + +100 mg / kg / day verapamil, HSALR / Mbnl- / - +vehicle, and HSALR / Mbnl1- / - +100 mg / kg / day verapamil. Figure 31B shows the average weekly body weight change. Figure 31C shows weekly righting reflex time analysis of HSALR / Mbnl1+ / + +vehicle, HSALR / Mbnl1+ / + +100 mg / kg / day verapamil, HSALR / Mbnl- / - +vehicle, and HSALR / Mbnl1- / - +100 mg / kg / day verapamil. Symbols, filled circles, and errors, mean±SEM. [Fig. 32A-32C] A series of graphs showing that the combination of HSALR and Mbnl1- / - is synthetically lethal, resulting in significant reductions in survival and body weight, and increased time to righting. Amlodipine treatment significantly improved survival and time to righting. Figure 32A shows the results of Kaplan-Meier survival analysis of HSALR / Mbnl1+ / + +vehicle, HSALR / Mbnl1+ / + +100 mg / kg / day amlodipine, HSALR / Mbnl- / - +vehicle, and HSALR / Mbnl1- / - +100 mg / kg / day amlodipine. Untreated HSALR / Mbnl1- / - mice had a significantly reduced life span. Figure 32B shows the average weekly weight change. Figure 32B shows weekly righting reflex time analysis of HSALR / Mbnl1+ / + +vehicle, HSALR / Mbnl1+ / + +100mg / kg / day amlodipine, HSALR / Mbnl- / - +vehicle, and HSALR / Mbnl1- / - +100mg / kg / day amlodipine. Statistical analysis: One-way or two-way ANOVA with multiple comparisons was used to test for significant differences between each of the groups tested. For survival, each group was compared with the Kaplan-Meier log-rank test of each other group. Please note that for the asterisks in all figures, the p-values were used as follows: *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] The present disclosure relates to the unexpected discovery that agents capable of inhibiting calcium channels, such as calcium channel blockers, are effective in treating or alleviating the symptoms of myotonic disorders. In patients diagnosed with the condition, the methods of the disclosure can, for example, reverse or inhibit the worsening of symptoms associated with such conditions and / or prevent the emergence of new symptoms.
[0021] Methods for treating myotonic disorders Thus, the present disclosure provides a method for treating myotonic disorder in a subject in need of such treatment.In some embodiments, the method of the present disclosure uses calcium channel blockers to reverse or prevent symptoms of myotonic disorder (e.g., muscular dystrophy, including myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2)) by inhibiting transient paralysis, a state of post-myotonic paralysis caused by Cav1.1 activity, or / and reducing the short-term and / or long-term harm of myotonic-associated calcium influx to muscle structure or force-generating ability.In some embodiments, the method is effective for treating muscular dystrophy patients by reducing muscle pain, stiffness, weakness, or delayed relaxation, and protecting against long-term muscle deterioration.
[0022] As used herein, the term "muscle tone" refers to any disorder or condition characterized by tonic spasms or temporary stiffening of muscles, especially reduced relaxation of muscles after sustained contraction. Examples of disorders that exhibit muscle tone include myotonic dystrophy, myotonia congenita, and paramyotonia congenita.
[0023] As used herein, the term "dystrophy" refers to any disorder or condition, particularly a genetic condition, characterized by degeneration of tissue, such as muscle tissue. In some embodiments, examples of muscular dystrophies include Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
[0024] As used herein, the term "muscular dystrophy" refers to any genetic condition or disorder that affects skeletal muscles and is characterized by progressive muscle weakness, loss of muscle protein, and ultimately muscle cell death. This term broadly encompasses any condition with at least one, and typically more, symptoms, including muscle pain, muscle weakness, muscle stiffness, difficulty walking, muscle tone, fatigue, scoliosis, axonal peripheral neuropathy, cardiomyopathy, cardiac arrhythmia, mental retardation, hypersomnia, sleep apnea, iris posterior subcapsular cataract, insulin insensitivity, type II diabetes mellitus, premature hair loss, testicular insufficiency, infantile hypotonia, and respiratory failure. Not all symptoms need to be present. For example, a person with muscular dystrophy may have cataracts or mild muscle tone, but may not have muscle weakness or cardiac arrhythmia. Similarly, a person with muscular dystrophy may have muscle pain and weakness, but may not have hypersomnia or sleep apnea.
[0025] As used herein, the term "myotonic dystrophy type 1" or "DM1" is also known as Steinert's disease, a condition in which patients have an abnormally large number of CTG repeats in their DMPK gene. Typically, symptoms are observed in individuals with 50 or more CTG repeats. DM1 includes patients with mild, classical, and congenital forms (phenotypes) of the disease.
[0026] As used herein, the terms "myotonic dystrophy type 2", "DM2", "proximal myotonic myopathy", and "PROMM" refer to a condition in which patients have an abnormally high number of CCTG repeats in the CNBP (ZNF9) gene. Systemic symptoms are observed in individuals with at least 75 CCTG repeats.
[0027] Typically, the number and severity of muscular dystrophy symptoms depend on the type and severity of gene defect.For example, in DM1, as CTG copy number increases, the age at which symptoms appear decreases, and patients with higher copy number have more severe symptoms at a certain age compared to patients with lower copy number.In milder forms of the disease, patients may be asymptomatic at first, and when they reach adolescence or adulthood, they may show physical symptoms of the disease.
[0028] In some embodiments, the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia. In some embodiments, the myotonic dystrophy is myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2). In some embodiments, the myotonic dystrophy is associated with abnormal alternative splicing of RNA encoding the CIC-1 chloride channel or the Cav1.1 calcium channel. Cav1.1, also known as calcium channel, voltage-dependent, L-type, alpha 1S subunit (CACNA1S, Uniprot accession code: Q13698), is a protein encoded by the CACNA1S gene in humans.
[0029] In some embodiments, the congenital myotonia is Becker or Thomsen congenital myotonia. In some embodiments, the sodium channel myotonia is paramyotonia congenita, hyperkalemic periodic paralysis, or potassium-induced myotonia. In some embodiments, the subject has one or more mutations in SCN4A, Clcn1, or Cac1ns, or has alternative splice isoforms of Clcn1 or Cac1ns.
[0030] In some embodiments, the method includes administering to the subject a therapeutically effective amount of an agent (e.g., a calcium channel blocker) that inhibits a calcium channel (e.g., a Cav1.1 calcium channel) in a cell of the subject. In some embodiments, the agent includes a calcium channel blocker, a stereoisomer thereof, a derivative / analog thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof, or a combination thereof.
[0031] As used herein, the terms "calcium channel blocker", "channel antagonist", "calcium channel inhibitor" or "calcium entry blocker" refer to agents that block voltage-dependent calcium channels. Exemplary calcium channel blockers include, but are not limited to, amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine, nivaldipine, ryosidine, anipamil, diltiazem, fendiline, flunarizine, gallopamil, mibefradil, prenylamine, tiapamil, verapamil, perhexiline maleate, fendiline, prenylamine, stereoisomers, derivatives thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
[0032] In some embodiments, the agent is selected from verapamil, amlodipine, diltiazem, nifedipine, stereoisomers, derivatives thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
[0033] Verapamil has the IUPAC name (RS)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]-(methyl)amino}-2-prop-2-ylpentanenitrile and the following chemical formula: [ka]
[0034] Amlodipine has the IUPAC name (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate and the following chemical formula: [ka]
[0035] Diltiazem has the IUPAC name cis-(+)-[2-(2-dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2-azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate, and the following chemical formula: [ka]
[0036] Nifedipine has the IUPAC name 3,5-dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and the following chemical formula: [ka]
[0037] As used herein, the terms "treating", "treat" and "treatment" include (i) preventing the occurrence (e.g., prophylaxis) of a disease, pathological or medical condition, (ii) inhibiting or halting the appearance of a disease, pathological or medical condition, (iii) alleviating or ameliorating a disease, pathological or medical condition, and / or (iv) reducing symptoms associated with a disease, pathological or medical condition. Thus, the terms "treat", "treatment" and "treating" can be expanded to prophylaxis and can include preventing, prevention, reducing, halting or reversing the progression or severity of the condition or symptoms being treated. Thus, the term "treatment" can include medical, therapeutic and / or prophylactic administration, as appropriate. Thus, the term "treating" or "treatment" can include reversing, reducing or halting symptoms, clinical signs and underlying pathology of a condition in a manner that improves or stabilizes the condition of the subject.
[0038] As used herein, the term "ameliorate" refers to the effect of administering an agent to a patient (e.g., a myotonic dystrophy patient) that results in any indication of success in preventing, reducing, or reversing one or more symptoms associated with a condition. Reduction may be indicated by lower severity, delayed onset of symptoms, or slowing of disease progression. Prevention, reduction, or reversal of symptoms can be measured based on objective parameters, such as the results of a physical or clinical examination (i.e., blood tests), reduced need for medication, support measures (i.e., reduced need for the use of a ventilator), or increased mobility. Prevention, reduction, or reversal of symptoms can also be measured based on subjective parameters, such as reduced pain or stiffness, or increased mobility and well-being of the patient.
[0039] As used herein, the term "administering" refers to the delivery of cells by any route, including, but not limited to, oral, intranasal, intraocular, intravenous, intraosseous, intraperitoneal, intraspinal, intramuscular, intraarticular, intraventricular, intracranial, intralesional, intratracheal, intrathecal, subcutaneous, intradermal, transdermal, or transmucosal administration.
[0040] In some embodiments, the agent is administered to the subject intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, sublingually, sustained release, controlled release, delayed release, or as a suppository.
[0041] "Effective amount" refers to an amount effective to treat a disease, disorder, and / or condition or to produce a recited effect. For example, an effective amount can be an amount effective to reduce the progression or severity of the condition or symptom being treated. Determination of a therapeutically effective amount is well within the capabilities of one of ordinary skill in the art. The term "effective amount" is intended to include, for example, an amount of a compound described herein, or an amount of a combination of compounds described herein, that is effective to treat or prevent a disease or disorder in a host, or to treat a symptom of a disease or disorder. Thus, an "effective amount" generally means an amount that provides a desired effect. A "therapeutically effective amount" of a compound in relation to the subject treatment methods refers to an amount of a compound in a preparation that, when administered (to a mammal, e.g., a human) as part of a desired dosing regimen, alleviates symptoms, improves condition, or slows the onset of a disease state, according to clinically accepted criteria for the disorder or condition being treated, at a reasonable benefit / risk ratio applicable to any medical treatment.
[0042] The compound may be administered in a unit dosage form, for example, in a dosage form of 5 to 1000 mg / m 2 , conveniently 10 to 750 mg / m 2 , most conveniently 50-500 mg / m 2 The active ingredient can be conveniently administered in a unit dosage form containing the active ingredient. In some embodiments, the dose can be presented as a single dose or as divided doses administered at appropriate intervals, e.g., as two, three, four or more sub-doses per day. The sub-dose itself can be further divided, e.g., into several discrete loosely spaced administrations.
[0043] The actual dosage of the composition of the present invention administered to a patient may be determined by physical and physiological factors such as body weight, severity of the condition, type of disease being treated, previous or concurrent therapeutic interventions, idiopathic disease of the patient, and route of administration. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in the composition and appropriate dose for the individual subject.
[0044] In some embodiments, the method includes administering to the subject one or more doses of the agent, including from 0.1 mg / kg / body weight to about 1000 mg / kg / body weight or more, e.g., about 0.1 mg / kg / body weight, 0.5 mg / kg / body weight, 1 mg / kg / body weight, about 5 mg / kg / body weight, about 10 mg / kg / body weight, about 20 mg / kg / body weight, about 30 mg / kg / body weight, about 40 mg / kg / body weight, about 50 mg / kg / body weight, about 75 mg / kg / body weight, about 100 mg / kg / body weight, about 200 mg / kg / body weight, about 350 mg / kg / body weight, about 500 mg / kg / body weight, about 750 mg / kg / body weight to about 1000 mg / kg / body weight or more, or any range derivable therein.
[0045] In some embodiments, the agent is administered at a dose of about 0.01 to about 100 mg / kg of the subject's body weight (e.g., about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 11 mg / kg, about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, about 18 mg / kg, about 19 mg / kg, about 20 mg / kg, about 21 mg / kg, about 22 mg / kg, about 23 mg / kg, about 24 mg / kg, about 25 mg / kg, about 26 mg / kg, about 27 mg / kg, about 28 mg / kg, about 29 mg / kg, about 30 mg / kg, about 31 mg / kg, about 32 mg / kg, about 33 mg / kg, about 34 mg / kg, about 35 mg / kg, about 36 mg / kg, about 37 mg / kg, about 38 mg / kg, about 39 mg / kg, about 40 mg / kg, about 41 mg / kg, about 42 mg / kg, about 43 mg / kg, about 44 mg / kg, about 45 mg / kg, about 46 mg / kg, about 47 mg / kg, about 48 mg / kg, about 49 mg / kg, about 50 mg / kg, about 51 mg / kg, about 52 mg / kg, about 53 mg / kg, about 54 mg / kg, about 55 mg / kg, about 56 mg / kg, about 57 mg / kg, about 58 mg / kg, about 59 mg / kg, about 60 mg / kg, / kg, about 24mg / kg, about 25mg / kg, about 26mg / kg, about 27mg / kg, about 28mg / kg, about 29mg / kg, about 30mg / kg, about 31mg / kg, about 32mg / kg, about 33mg / kg, about 34mg / kg, about 35mg / kg, about 36mg / kg kg, about 37mg / kg, about 38mg / kg, about 39mg / kg, about 40mg / kg, about 41mg / kg, about 42mg / kg, about 43mg / kg, about 44mg / kg, about 45mg / kg, about 46mg / kg, about 47mg / kg, about 48mg / kg, about 49mg / k g, about 50mg / kg, about 51mg / kg, about 52mg / kg, about 53mg / kg, about 54mg / kg, about 55mg / kg, about 56mg / kg, about 57mg / kg, about 58mg / kg, about 59mg / kg, about 60mg / kg, about 61mg / kg, about 62mg / kg , about 63mg / kg, about 64mg / kg, about 65mg / kg, about 66mg / kg, about 67mg / kg, about 68mg / kg, about 69mg / kg, about 70mg / kg, about 71mg / kg, about 72mg / kg, about 73mg / kg, about 74mg / kg, about 75mg / kg, In some embodiments, the agent is administered to the subject in one or more doses of about 1 to about 50 mg / kg of the subject's body weight.In some embodiments, the agent is administered in one or more doses of about 8 to about 16 mg / kg of subject body weight.
[0046] In some embodiments, one or more doses of the agent are administered at least every 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, or more than every 1 day. every 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st and every 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd
[0043] In some embodiments, the dose is administered every 94 days, 95 days, 96 days, 97 days, 98 days, 99 days, 100 days, 101 days, 102 days, 103 days, 104 days, 105 days, 106 days, 107 days, 108 days, 109 days, 110 days, 111 days, 112 days, 113 days, 114 days, 115 days, 116 days, 117 days, 118 days, 119 days, or 120 days.
[0047] In some embodiments, the treatment results in a therapeutic effect selected from reduced muscle tone, reduced weight loss, improved survival, improved muscle function, improved righting time, improved respiratory function, and improved diaphragm strength, hi some embodiments, the treatment results in at least a 50% improvement in muscle tone, weight loss, survival, muscle function, righting time, respiratory function, or diaphragm strength compared to untreated subjects.
[0048] The term "therapeutic effect" is recognized in the art and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans, caused by a pharmacologically active substance. The phrase "therapeutically effective amount" refers to an amount of such a substance that produces some desired local or systemic effect at a reasonable benefit / risk ratio applicable to any treatment. The therapeutically effective amount of such a substance varies depending on the subject and the disease or condition being treated, the subject's weight and age, the severity of the disease or condition, the method of administration, and the like, which can be readily determined by one of skill in the art. For example, certain compositions described herein can be administered in an amount sufficient to produce the desired effect at a reasonable benefit / risk ratio applicable to such treatment.
[0049] In another aspect, the present disclosure also provides the use of the agent that inhibits calcium channel in the manufacture of a medicament for treating myotonic disorder in a subject in need thereof.In some embodiments, the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia.In some embodiments, the calcium channel is Cav1.1 calcium channel.
[0050] In some embodiments, the drug is selected from verapamil, amlodipine, diltiazem, nifedipine, a stereoisomer thereof, a derivative / analog thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof, or a combination thereof.
[0051] Pharmaceutical Compositions and Kits The disclosure also provides a pharmaceutical composition comprising (i) the above-mentioned agent (e.g., a calcium channel blocker), a stereoisomer thereof, a derivative / analog thereof, a prodrug thereof, a metabolite thereof, or a pharma- ceutically acceptable salt thereof, and (ii) optionally, a pharma- ceutically acceptable carrier.
[0052] In some embodiments, for example, the pharmaceutical compositions described herein for treating a myotonic disorder in a subject in need thereof comprise a calcium channel blocker selected from verapamil, amlodipine, diltiazem, nifedipine, stereoisomers thereof, derivatives / analogs thereof, prodrugs thereof, metabolites thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
[0053] In some embodiments, pharmaceutical compositions may contain, for example, at least about 0.1% of a compound. In other embodiments, the active compound may comprise between about 2% to about 75%, or between about 25% to about 60%, of the weight of the unit, and any range derivable therein.
[0054] In some embodiments, the pharmaceutical composition further comprises one or more agents selected from ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, lamotrigine, stereoisomers thereof, derivatives / analogs thereof, prodrugs thereof, metabolites thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
[0055] As used herein, the term "composition" or "pharmaceutical composition" refers to a mixture of at least one component useful within the present invention with other components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. A pharmaceutical composition facilitates administration of one or more components of the present invention to an organism.
[0056] In some embodiments, the agents (e.g., calcium channel blockers) used herein may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that serves as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms. "R" and "S" represent the configuration of the substituents around one or more chiral carbon atoms. Thus, "R*" and "S*" indicate the relative configuration of the substituents around one or more chiral carbon atoms. The symbol "*" in a structural formula represents the presence of a chiral carbon center.
[0057] A "racemate" or "racemic mixture" means a compound of equimolar amounts of two enantiomers and such mixtures exhibit no optical activity, i.e., they do not rotate the plane of polarized light.
[0058] "Geometric isomer" means an isomer that differs in the orientation of substituent atoms in relationship to a carbon-carbon double bond, a cycloalkyl ring, or a bridged bicyclic system. The atoms (other than H) on each side of a carbon-carbon double bond can be in the E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. "R", "S", "St", "R*", "E", "Z", "cis", and "trans" refer to configurations relative to the core molecule.
[0059] The compounds of the present invention can be prepared as individual isomers by isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming a salt of the free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming a salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each isomer of an isomeric pair using an optically pure acid, amine, or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving the isomeric mixture of either the starting material or the final product using a variety of well-known chromatographic methods.
[0060] When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight relative to other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% optically pure by weight. Percent optical purity is the ratio of the weight of the enantiomer to the weight of the enantiomer plus the weight of its optical isomer.
[0061] Where a disclosed compound is named or depicted by structure without indicating stereochemistry, and the compound has at least one chiral center, the name or structure should be understood to encompass one enantiomer of the compound free of the corresponding optical isomer, racemic mixtures of the compounds, and mixtures enriched in one enantiomer with respect to the corresponding optical isomer.
[0062] When a disclosed compound is named or depicted by structure without indicating stereochemistry and has at least two chiral centers, the name or structure should be understood to encompass diastereomers free of the other diastereomer, pairs of diastereomers free of the other diastereomer pair, mixtures of diastereomers, mixtures of diastereomer pairs, mixtures of diastereomers where one diastereomer is enriched relative to the other, and mixtures of diastereomer pairs where one diastereomer pair is enriched relative to the other.
[0063] As used herein, the term "derivative" refers to a chemical that is structurally related to another, i.e., "original" substance, which may be referred to as the "parent" compound. A "derivative" may be made from a structurally related parent compound in one or more steps. The phrase "closely related derivative" refers to a derivative whose molecular weight does not exceed the weight of the parent compound by more than 50%. The general physical and chemical properties of closely related derivatives are also similar to the parent compound. A "pharmacologically active derivative" refers to any compound that, upon administration to a recipient, can directly or indirectly provide the activity disclosed herein.
[0064] The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio.
[0065] As used herein, the term "pharmaceutically acceptable salts" refers to salts of the compound being administered prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof.
[0066] Compounds can form salts, which are also within the scope of the present disclosure. Unless otherwise indicated, reference to a compound of the present invention is understood to include reference to one or more salts thereof. The term "salt" refers to acidic and / or basic salts formed with inorganic and / or organic acids and bases. In addition, the term "salt" can include zwitterions (inner salts), for example, when the compound contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as acceptable metal salts and amine salts, whose cations do not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, for example, in isolation or purification steps that may be used during preparation, and are therefore contemplated within the scope of the present disclosure. Salts of compounds can be formed, for example, by reacting the compound with an equivalent amount of acid or base in a medium, such as a medium in which the salt precipitates, or in an aqueous medium (followed by lyophilization).
[0067] Exemplary acid addition salts include acetates (e.g., those formed with acetic acid or trihaloacetic acids, e.g., trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecyl sulfate, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), iodides, and the like. Examples of suitable salts include hydrochlorides, maleates (formed with maleic acid), 2-hydroxyethanesulfonates, lactates, methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates, e.g., tosylates, undecanoates, and the like.
[0068] Exemplary base salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, barium, zinc, and aluminum salts, salts with organic bases (e.g., organic amines) such as trialkylamines, e.g., triethylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine, or similar pharma- ceutically acceptable amines, and salts with amino acids such as arginine, lysine, and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), etc. In some embodiments, example salts include monohydrochlorides, hydrogen sulfates, methanesulfonates, phosphates, or nitrates.
[0069] Various forms of prodrugs are well known in the art and are described in: (a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); (b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985); (c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113-191 (Harwood Academic Publishers, 1991); and (d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003).
[0070] In addition, the compounds may be isolated and purified after their preparation to obtain compositions containing 99% by weight or greater of the compound ("substantially pure"), which may then be used or formulated as described herein. Such "substantially pure" compounds are also contemplated herein as part of the disclosure.
[0071] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and to survive formulation into an efficacious therapeutic agent. The present disclosure is intended to embody stable compounds.
[0072] The compounds of the present disclosure are intended to include all isotopes of atoms present in the compounds. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13 C and 14C. Isotopically labeled compounds of the present disclosure may generally be prepared by conventional techniques known to those of skill in the art, or by processes similar to those described herein, using the appropriate isotopically labeled reagent in place of an otherwise non-labeled reagent. For example, methyl (-CH3) also includes deuterated methyl groups, such as -CD3.
[0073] The compounds and / or their pharmaceutically acceptable salts may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or the amount of compound to be delivered. Also included within the present disclosure is a class of pharmaceutical compositions that contain the compounds and / or their pharmaceutically acceptable salts, and one or more non-toxic pharmaceutically acceptable carriers and / or diluents and / or adjuvants (collectively referred to herein as "carrier" materials), and, if desired, other active ingredients. The compounds may be administered by any suitable route, for example, in the form of a pharmaceutical composition adapted to such route, and in a dose effective for the intended treatment. The compounds and compositions of the present disclosure may be administered orally, mucosally, rectally, or parenterally, including, for example, intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the pharmaceutical carrier may contain a mixture of mannitol or lactose with microcrystalline cellulose. The mixture may contain additional components such as a lubricant, e.g., magnesium stearate, and a disintegrant, e.g., crospovidone. The carrier mixture may be filled into a gelatin capsule or compressed into a tablet. The pharmaceutical composition may be administered, for example, as an oral dosage form or injection.
[0074] Techniques and formulations can generally be found in Remmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the agent can be formulated in a liquid solution, such as Hank's solution or Ringer's solution, which is a physiologically compatible buffer. In addition, the agent can be formulated in solid form and redissolved or suspended immediately before use. Lyophilized forms are also included.
[0075] For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is made, for example, in the form of a dosage unit containing a specific amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule containing an amount of active ingredient ranging from about 0.1 to 1000 mg, for example, from about 0.25 to 250 mg, and for example, from about 0.5 to 100 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but can be determined using routine methods.
[0076] Any pharmaceutical composition contemplated herein can be delivered orally, for example, via any acceptable suitable oral preparation. Exemplary oral preparations include, but are not limited to, for example, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared according to any method known in the art for producing pharmaceutical compositions intended for oral administration. In order to provide a pharma-ceutical palatable preparation, pharmaceutical compositions according to the present disclosure can contain at least one agent selected from sweeteners, flavoring agents, coloring agents, demulcents, antioxidants, and preservatives.
[0077] Tablets can be prepared, for example, by mixing at least one compound and / or at least one pharma- ceutically acceptable salt thereof with at least one non-toxic pharma- ceutically acceptable excipient suitable for tablet manufacture. Exemplary excipients include, but are not limited to, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents such as microcrystalline cellulose, croscarmellose sodium, corn starch, and alginic acid; binding agents such as starch, gelatin, polyvinylpyrrolidone, and acacia; and lubricants such as magnesium stearate, stearic acid, and talc. Additionally, tablets can be uncoated or coated by known techniques to either mask the unpleasant taste of unpleasant tasting drugs or to delay disintegration and absorption of the active ingredient in the gastrointestinal tract, thereby prolonging the effect of the active ingredient. Exemplary water-soluble taste-masking materials include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose. Exemplary time delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.
[0078] Hard gelatin capsules can be prepared, for example, by mixing at least one compound and / or at least one salt thereof with at least one inert solid diluent, such as calcium carbonate, calcium phosphate, and kaolin.
[0079] Soft gelatin capsules can be prepared, for example, by mixing at least one compound and / or at least one pharma- ceutically acceptable salt thereof with at least one water-soluble carrier, such as, for example, polyethylene glycol, and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.
[0080] Aqueous suspensions can be prepared, for example, by mixing at least one compound and / or at least one pharma- ceutically acceptable salt thereof with at least one excipient suitable for the manufacture of aqueous suspensions.Exemplary excipients suitable for the manufacture of aqueous suspensions include, but are not limited to, suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia, dispersing agents or wetting agents, for example, naturally occurring phosphatides, for example, lecithin, condensation products of alkylene oxides with fatty acids, for example, polyoxyethylene stearates, condensation products of ethylene oxide with long chain fatty alcohols, for example, heptadecaethylene-oxycetanol, condensation products of ethylene oxide with partial esters derived from fatty acids and hexitols, for example, polyoxyethylene sorbitol monooleate, and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate, at least one coloring agent, at least one flavoring agent, and / or at least one sweetening agent, including, for example, but not limited to, sucrose, saccharin, and aspartame.
[0081] Oil suspensions can be prepared, for example, by suspending at least one compound and / or at least one pharma- ceutically acceptable salt thereof in a vegetable oil, such as, for example, peanut oil, olive oil, sesame oil, and coconut oil, or in a mineral oil, such as, for example, liquid paraffin. Oil suspensions can also contain at least one thickening agent, such as, for example, beeswax, hard paraffin, and cetyl alcohol. To provide a palatable oil suspension, at least one of the sweeteners already described above and / or at least one flavoring agent can be added to the oil suspension. Oil suspensions can further contain at least one preservative, including, but not limited to, for example, an antioxidant, such as, for example, butylated hydroxyanisole and alpha-tocopherol.
[0082] Dispersible powders and granules can be prepared, for example, by mixing at least one compound and / or at least one pharma- ceutically acceptable salt thereof with at least one dispersing agent and / or wetting agent, at least one suspending agent, and / or at least one preserving agent. Suitable dispersing agents, wetting agents, and suspending agents have already been described above. Exemplary preservatives include, but are not limited to, for example, antioxidants, such as ascorbic acid. In addition, dispersible powders and granules can also contain at least one excipient, including, but are not limited to, for example, sweeteners, flavoring agents, and coloring agents.
[0083] The emulsion of at least one compound and / or at least one pharma- ceutically acceptable salt thereof can be prepared, for example, as an oil-in-water emulsion. The oily phase of the emulsion containing the compound can be composed of known ingredients in a known manner. The oily phase can be provided, for example, but not limited to, vegetable oil, for example, olive oil, peanut oil, mineral oil, for example, liquid paraffin, and mixtures thereof. The phase can comprise a simple emulsifier, but can also comprise a mixture of at least one emulsifier with a fat or oil, or both a fat and an oil. Suitable emulsifiers include, but are not limited to, for example, naturally occurring phosphatides, for example, soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. In some embodiments, a hydrophilic emulsifier is included together with a lipophilic emulsifier that functions as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifiers, with or without stabilizers, constitute the so-called emulsifying waxes, and the waxes, together with oils and fats, constitute the so-called emulsifying ointment bases that form the oily dispersed phase of cream formulations.The emulsions can also contain sweeteners, flavorings, preservatives, and / or antioxidants.Emulsifiers and emulsion stabilizers suitable for use in the formulations of the present disclosure include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate, or other materials known in the art, either alone or with waxes.
[0084] The pharmaceutical compositions described herein can also be incorporated into topical formulations containing topical carriers, which generally are suitable for topical drug administration and include any such material known in the art.Topical carriers can be selected to provide the composition in a desired form, for example, as an ointment, lotion, cream, microemulsion, gel, oil, solution, etc., and can be composed of materials of either natural or synthetic origin.Preferably, the selected carrier does not adversely affect the active agent or other components of the topical formulation.Examples of suitable topical carriers for use herein include water, alcohol and other non-toxic organic solvents, glycerin, mineral oil, silicone, petrolatum, lanolin, fatty acids, vegetable oils, parabens, waxes, etc.
[0085] Pharmaceutical compositions may be incorporated into gel formulations, which are generally semi-solid systems consisting of either a suspension composed of small inorganic particles (two-phase systems) or large organic molecules distributed substantially uniformly throughout a carrier liquid (single-phase gels). Single-phase gels can be made, for example, by combining together an active agent, a carrier liquid, and a suitable gelling agent, such as tragacanth (2-5%), sodium alginate (2-10%), gelatin (2-15%), methylcellulose (3-5%), sodium carboxymethylcellulose (2-5%), carbomer (0.3-5%), or polyvinyl alcohol (10-20%), and mixing until a characteristic semi-solid product is produced. Other suitable gelling agents include methylhydroxycellulose, polyoxyethylene-polyoxypropylene, hydroxyethylcellulose, and gelatin. Gels generally employ an aqueous carrier liquid, although alcohols and oils may also be used as carrier liquids.
[0086] The compound and / or at least one pharmaceutically acceptable salt thereof may also be delivered, for example, intravenously, subcutaneously, and / or intramuscularly, via any suitable pharmaceutically acceptable injectable form. Exemplary injectable forms include, but are not limited to, sterile aqueous solutions, sterile oil-in-water microemulsions, and aqueous or oily suspensions, including acceptable vehicles and solvents such as, for example, water, Ringer's solution, and isotonic sodium chloride solution.
[0087] Preparations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules by using one or more of the carriers or diluents mentioned for use in preparations for oral administration, or by using other suitable dispersing or wetting agents and suspending agents. The compound may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and / or various buffers. Other adjuvants and modes of administration are well known and widely known in the pharmaceutical field. The active ingredient may also be administered by injection as a composition with a suitable carrier including saline, dextrose, or water, or with cyclodextrins (i.e., Captisol), cosolvent solubilizers (i.e., propylene glycol), or micellar solubilizers (i.e., Tween 80).
[0088] Sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables.
[0089] Sterile injectable oil-in-water microemulsions can be prepared, for example, by (1) dissolving at least one compound in an oily phase, such as a mixture of soybean oil and lecithin, (2) combining the oily phase with a mixture of water and glycerol, and (3) processing the combination to form a microemulsion.
[0090] Sterile aqueous or oily suspensions can be prepared according to methods already known in the art. For example, sterile aqueous solutions or suspensions can be prepared with non-toxic parenterally acceptable diluents or solvents, such as 1,3-butanediol, and sterile oily suspensions can be prepared with sterile non-toxic acceptable solvents or suspension media, such as sterile fixed oils, such as synthetic monoglycerides or diglycerides, and fatty acids, such as oleic acid.
[0091] Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of the present disclosure include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as alpha-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as cremophor surfactant (BASF), or other similar polymeric delivery matrices, serum proteins such as human serum albumin, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulosic materials, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat. Cyclodextrins, such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives, such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrin, or other solubilizing derivatives, may also be advantageously used to enhance delivery of the compounds of the formulae described herein.
[0092] The pharma- ceutically active compounds of the present disclosure can be processed according to conventional pharmaceutical methods to produce medicaments for administration to patients, including humans and other mammals. The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization, and / or can contain conventional adjuvants, such as additives, preservatives, stabilizers, wetting agents, emulsifiers, buffers, and the like. Tablets and pills can additionally be prepared with enteric coatings. Such compositions can also contain adjuvants, such as wetting agents, sweeteners, flavoring agents, and aromatic agents.
[0093] Various additives known to those skilled in the art may be included in the formulation, e.g., topical formulation. Examples of additives include, but are not limited to, solubilizers, skin permeation enhancers, opacifiers, preservatives (e.g., antioxidants), gelling agents, buffers, surfactants (especially nonionic and amphoteric surfactants), emulsifiers, emollients, thickeners, stabilizers, moisturizers, colorants, fragrances, and the like. It is particularly preferred to include a solubilizer and / or skin permeation enhancer along with an emulsifier, emollient, and preservative. An optimal topical formulation will contain approximately 2% to 60% by weight, e.g., 2% to 50% by weight, solubilizer and / or skin permeation enhancer, 2% to 50% by weight, e.g., 2% to 20% by weight, emulsifier, 2% to 20% by weight, emollient, and 0.01 to 0.2% by weight, preservative, with the active agent and carrier (e.g., water) making up the remainder of the formulation. Skin permeation enhancers serve to facilitate the passage of therapeutic levels of an active agent through a reasonably sized area of unbroken skin. Suitable accelerators are well known in the art and include, for example, lower alkanols such as methanol, ethanol, and 2-propanol; alkyl methyl sulfoxides such as dimethyl sulfoxide (DMSO), decyl methyl sulfoxide (C.sub.10 MSO), and tetradecyl methyl sulfoxide; pyrrolidones such as 2-pyrrolidone, N-methyl-2-pyrrolidone, and N-(-hydroxyethyl)pyrrolidone; urea, N,N-diethyl-m-toluamide, C2.-C6 alkanediols, various solvents such as dimethylformamide (DMF), N,N-dimethylacetamide (DMA), and tetrahydrofurfuryl alcohol; and 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (laurocapram; available under the trademark Azone R™ from Whitby Research Incorporated, Richmond, Va.).
[0094] Examples of solubilizers include, but are not limited to, hydrophilic ethers such as diethylene glycol monoethyl ether (ethoxydiglycol, commercially available as Transcutol™) and diethylene glycol monoethyl ether oleate (commercially available as Softcutol™), polyethylene castor oil derivatives such as polyoxy 35 castor oil, polyoxy 40 hydrogenated castor oil, polyethylene glycols, especially low molecular weight polyethylene glycols such as PEG 300 and PEG 400, and polyethylene glycol derivatives such as PEG-8 caprylic / caprylic acid glyceride (commercially available as Labrasol™), alkyl methyl sulfoxides such as DMSO, pyrrolidones such as 2-pyrrolidone and N-methyl-2-pyrrolidone, and DMA. Many solubilizers can also function as absorption enhancers. A single solubilizer can be incorporated into the formulation, or a mixture of solubilizers can be incorporated therein.
[0095] Suitable emulsifiers and co-emulsifiers include, but are not limited to, those described for microemulsion formulations. Emollients include, for example, propylene glycol, glycerol, isopropyl myristate, polypropylene glycol-2 (PPG-2) myristyl ether propionate, and the like.
[0096] Other active agents, such as anti-inflammatory agents, analgesics, antibacterial agents, antifungal agents, antibiotics, vitamins, antioxidants, and sunscreens typically found in sunscreen formulations, may also be included in the formulation, including, but not limited to, anthranilates, benzophenones (especially benzophenone-3), camphor derivatives, cinnamates (e.g., octyl methoxycinnamate), dibenzoylmethanes (e.g., butyl methoxydibenzoylmethane), p-aminobenzoic acid (PABA) and its derivatives, and salicylic acid (e.g., octyl salicylate). In certain topical formulations, the active agent may be present in an amount ranging from about 0.25% to 75% by weight of the formulation, such as from about 0.25% to 30% by weight of the formulation, such as from about 0.5% to 15% by weight of the formulation, and for example from about 0.5% to 15% by weight of the formulation. For example, it is present in an amount ranging from about 1.0% to 10% by weight of the formulation. The topical skin treatment composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or cream can be packaged in a bottle or roll-ball applicator, or a propellant-driven aerosol device, or a container fitted with a pump suitable for finger operation. If the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a jar with a lid. The composition may also be contained in a capsule as described in U.S. Pat. No. 5,063,507. Thus, there is also provided a sealed container containing a cosmetically acceptable composition.
[0097] The amount of compound administered and the dosing regimen for treating a disease state with the compounds and / or compositions of the present disclosure will depend on a variety of factors, including age, weight, sex, medical condition of the subject, type of disease, severity of disease, route and frequency of administration, and the particular compound used. Thus, dosing regimens can vary widely, but can be routinely determined using standard methods. Daily doses of about 0.001 to 100 mg / kg body weight, such as about 0.0025 to about 50 mg / kg body weight, and for example, about 0.005 to 10 mg / kg body weight, may be appropriate. Daily doses may be administered in one to four doses per day. Other dosing schedules include administration once a week and once every two-day cycle.
[0098] For therapeutic purposes, the active compound of the present disclosure is usually combined with one or more adjuvants suitable for the indicated administration route.When administered orally, the compound can be mixed with lactose, sucrose, starch powder, cellulose ester of alkanoic acid, cellulose alkyl ester, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfate, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and then tableted or sealed for convenient administration.Such capsules or tablets can contain controlled release formulations that can be provided in the dispersion of the active compound in hydroxypropylmethylcellulose.
[0099] The pharmaceutical compositions of the present disclosure comprise at least one compound and / or at least one pharma- ceutically acceptable salt thereof, and optionally an additional agent selected from any pharma- ceutically acceptable carrier, adjuvant, and vehicle. Another composition of the present disclosure comprises a compound described herein, or a prodrug thereof, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle.
[0100] The compounds, compositions, or pharmaceutical compositions described herein may be provided in a kit. In one embodiment, the kit also includes (a) a container containing the composition, and optionally (b) informational material. The informational material may be descriptive, instructional, marketing, or other material related to the methods described herein and / or the use of the agent for therapeutic benefit. For example, the kit may include instructions for manufacture, instructions for the therapeutic regimen to be used, and instructions for the duration of administration. In one embodiment, the kit also includes an additional therapeutic agent. The kit may include one or more containers, each with a different reagent. For example, the kit includes a first container containing the composition, and a second container for the additional therapeutic agent.
[0101] The container can contain a unit dosage of the pharmaceutical composition. In addition to the composition, the kit can contain other components such as a solvent or buffer, an adjuvant, a stabilizer, or a preservative. The kit optionally includes a device suitable for administering the composition, such as a syringe or other suitable delivery device. The device can be provided preloaded with one or both agents, or can be empty but suitable for loading.
[0102] Combination therapy The active ingredients described herein (e.g., verapamil, ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, and lamotrigine) may also be used in combination with other active ingredients. Such combinations may be selected based on the condition being treated, cross-reactivities of the ingredients, and the pharmaceutical properties of the combination.
[0103] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent or therapy. In some embodiments, the additional therapeutic agent is selected from ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, lamotrigine, and combinations thereof. In some embodiments, the additional therapeutic agent or therapy is administered to the subject before, after, or simultaneously with the agent.
[0104] As used herein, "combination" therapy is meant to include the coordinate administration of two or more therapeutic agents, unless otherwise clear from the context, including but not limited to simultaneous administration. Specifically, combination therapy includes both co-administration (e.g., administration of a co-formulation or simultaneous administration of separate therapeutic compositions) and sequential or sequential administration, provided that the administration of one therapeutic agent is in some way conditioned on the administration of another therapeutic agent. For example, one therapeutic agent may be administered only after a different therapeutic agent has been administered and allowed to act for a predetermined period of time. See, for example, Kohrt et al. (2011) Blood 117:2423.
[0105] As used herein, the term "co-administration" or "co-administered" refers to the administration of at least two agents or therapies to a subject. In some embodiments, the co-administration of two or more agents / therapies is simultaneous. In other embodiments, a first agent / therapy is administered prior to a second agent / therapy. Those skilled in the art will appreciate that the formulations and / or routes of administration of the various agents / therapies used may vary.
[0106] The compounds of the present invention may also be combined with one or more other active ingredients in a single dosage form for simultaneous or sequential administration to a patient. The combination therapy may be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more doses.
[0107] Combination therapy can provide synergistic effects, and can be synergistic, i.e., the effect achieved when the active ingredients used together exceed the sum of the effects resulting from using the compounds separately.Synergistic effects can be achieved when the active ingredients are (1) co-formulated in a combination preparation and administered or delivered simultaneously, (2) delivered in parallel as alternating or separate preparations, or (3) by some other regimen.When delivered in alternating therapy, synergistic effects can be achieved when the compounds are administered or delivered sequentially, for example, in separate tablets, pills, or capsules, or by different injections in separate syringes.Generally, during alternating therapy, the effective dosage of each active ingredient is administered sequentially, i.e., sequentially, whereas in combination therapy, the effective dosages of two or more active ingredients are administered together.Synergistic effects refer to effects that exceed the expected purely additive effects of the individual compounds of the combination.
[0108] Combination therapy is further described by U.S. Pat. Nos. 1,110,3514, 10,702,495, 9,382,215, and 6,833,373, including additional active agents that may be combined with the compounds described herein, and additional types of diseases and other conditions that may be treated with the compounds or combinations of compounds described herein.
[0109] Thus, it is an aspect of the present invention that the active agent (e.g., verapamil, ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, and lamotrigine) may be used in combination with another agent or treatment method. The active agent may precede or follow the treatment of the other agent by intervals ranging from minutes to weeks. In embodiments in which the other agent and the expression construct are applied separately to the cell, it is generally ensured that no significant period of time passes between the time of each delivery so that the agent and the expression construct can still exert their advantageously combined effect on the cell. For example, in such instances, it is contemplated that two, three, four or more modalities may be contacted with a cell, tissue, or organism substantially simultaneously (i.e., within less than about one minute) with the disclosed activity.
[0110] In some embodiments, the one or more agents may be administered within about 1 minute, within about 5 minutes, within about 10 minutes, within about 20 minutes, within about 30 minutes, within about 45 minutes, within about 60 minutes, within about 2 hours, within about 3 hours, within about 4 hours, within about 6 hours, within about 8 hours, within about 9 hours, within about 12 hours, within about 15 hours, within about 18 hours, within about 21 hours, within about 24 hours, within about 28 hours, within about 31 hours, within about 35 hours, within about 38 hours, within about 42 hours, within about 45 hours, within about 48 hours or more before and / or after administration of a disclosed active agent. In certain other embodiments, the agent may be administered within about 1, about 2, about 3, about 4, about 5, about 6, about 8, about 9, about 12, about 15, about 16, about 18, about 20 to about 21 days before and / or after administration of the disclosed active agent. In some circumstances, it may be desirable to extend the treatment period significantly, although several weeks (e.g., about 1, about 2, about 3, about 4, about 6, or about 8 weeks or more) pass between each administration.
[0111] The administration of the composition of the present invention to patients follows the general protocol for administration of therapeutic drugs, taking into account any toxicity.It is expected that the treatment cycle will be repeated as necessary.It is also contemplated that various standard or adjunctive therapies, as well as surgical interventions, can be applied in combination with the described active agents.These therapies include, but are not limited to, chemotherapy, radiation therapy, immunotherapy, gene therapy, and surgery.
[0112] definition To aid in the understanding of the detailed description of the compositions and methods according to the present disclosure, some explicit definitions are provided to facilitate a clear disclosure of the various aspects of the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0113] As used herein, "subject" or "subject in need thereof" refers to humans and non-human animals. Examples of non-human animals include all vertebrates, such as mammals, such as non-human mammals, non-human primates (especially higher primates), dogs, rodents (e.g., mice or rats), guinea pigs, cats, and rabbits, as well as non-mammals, such as birds, amphibians, and reptiles. In some embodiments, the subject is a human. In other embodiments, the subject is an animal suitable for use as an experimental animal or disease model.
[0114] As used herein, the term "disease" is intended to be generally synonymous with, and is used interchangeably with, the terms "disorder" and "condition" (in medical conditions), in that both reflect an abnormal condition of the human or animal body or parts thereof that impairs normal functioning, is typically manifested by clear signs and symptoms, and reduces the duration or quality of human or animal life.
[0115] Multiple techniques of administering a compound exist in the art, including, but not limited to, intravenous, oral, aerosol, parenteral, intraocular, intrapulmonary, and topical administration. "Parenteral" administration of a composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im), or intrasternal injection, or infusion techniques.
[0116] The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide, etc.), or an extract made from biological material such as a bacterial, plant, fungal, or animal (especially mammalian) cell or tissue. The activity of such agents may qualify as "therapeutic agents," which are biologically, physiologically, or pharmacologically active substances that act locally or systemically in a subject.
[0117] The terms "therapeutic agent," "therapeutic capable agent," or "treatment agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. Beneficial effects include enabling a diagnostic determination, ameliorating a disease, symptom, disorder, or pathological condition, reducing or preventing the onset of a disease, symptom, disorder, or condition, as well as generally combating a disease, symptom, disorder, or pathological condition.
[0118] As used herein, the term "pharmacologically acceptable" refers to a substance, such as a carrier or diluent, that does not abrogate the biological activity or properties of the composition and that is relatively non-toxic, i.e., the material may be administered to an individual without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0119] The term "pharmaceutically acceptable carrier" includes pharmaceutically acceptable salts, pharmaceutically acceptable materials, compositions, or carriers, such as liquid or solid fillers, diluents, excipients, solvents, or encapsulating materials, that are involved in the delivery or transport of a compound of the invention in or to a subject so that it may perform its intended function. Typically, such compounds are delivered or transported from one organ or part of the body to another. Each salt or carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Some examples of materials which can function as pharma- ceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol, glycerin, sorbitol, mannitol, and polysaccharides. Polyols such as ethylene glycol, esters such as ethyl oleate and ethyl laurate, agar, buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffer, diluents, granulating agents, lubricants, binders, disintegrants, wetting agents, emulsifiers, colorants, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, antioxidants, plasticizers, gelling agents, thickeners, hardeners, coagulants, suspending agents, surfactants, humectants, carriers, stabilizers, and non-toxic and compatible substances used in pharmaceutical preparations, or any combination thereof. As used herein, "pharmaceutical acceptable carrier" also includes any and all coating agents, antibacterial and antifungal agents, and absorption retardants, etc., that are compatible with the activity of the compound and are physiologically acceptable to the subject. Supplementary active compounds can also be incorporated into the composition.
[0120] The terms "sample", "test sample" and "patient sample" may be used interchangeably herein. A sample may be a sample of serum, urine plasma, amniotic fluid, cerebrospinal fluid, cells (e.g., antibody-producing cells), or tissue. Such samples may be used directly as obtained from a patient, or may be pretreated by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, etc. to modify the characteristics of the sample in some way, as discussed herein or otherwise known in the art. As used herein, the terms "sample" and "biological sample" generally refer to biological material that is tested for and / or suspected of containing an analyte of interest. A sample may be any tissue sample from a subject. A sample may include proteins from a subject.
[0121] As used herein, the terms "inhibit" and "antagonize" refer to reducing by a measurable amount or preventing completely the expression, stability, function, or activity of a molecule, reaction, interaction, gene, mRNA, and / or protein. Inhibitors are compounds, e.g., antagonists, that bind to, partially or completely block stimulation of, reduce, prevent, delay activation of, inactivate, desensitize, or downregulate proteins, genes, and mRNAs.
[0122] The terms "reduce", "reduced", "reduction", "reduce", or "inhibit" are all used herein to generally mean a reduction by a statistically significant amount. However, for the avoidance of doubt, "reduced", "reduce", "reduce", or "inhibit" means a reduction of at least 10% compared to a reference level, such as a reduction of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to 100% (e.g., absent levels compared to a reference sample), or any reduction between 10-100%.
[0123] As used herein, the term "modulate" is meant to refer to any change in a biological state, ie, an increase, a decrease, and the like.
[0124] The terms "increased", "increase", "enhance", or "activate" are all used herein to generally mean an increase of a statistically significant amount. For the avoidance of any doubt, the terms "increased", "increase", "enhance", or "activate" mean an increase of at least 10% compared to a reference level, for example, an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to 100%, or any increase between 10-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or about 10-fold, or any increase between 2-fold and 10-fold or more compared to a reference level.
[0125] Doses are often expressed relative to body weight. Thus, a dose expressed as [g, mg, or other unit] / kg (or g, mg, etc.) usually refers to [g, mg, or other unit] "per kg (or g, mg, etc.) of body weight," even if the term "body weight" is not explicitly mentioned.
[0126] As used herein, the term "in vitro" refers to events that take place not within a multicellular organism but in an artificial environment, such as in a test tube or reaction vessel, cell culture, etc.
[0127] As used herein, the term "in vivo" refers to events that take place within a multicellular organism, such as a non-human animal.
[0128] Please note that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0129] The terms "including," "comprising," "containing," or "having" and their conjugations are intended to encompass the items listed thereafter and equivalents thereof as well as additional subject matter, unless otherwise stated.
[0130] The phrases "in some embodiments," "various embodiments," and "in some embodiments" are used repeatedly. Such phrases do not necessarily refer to the same embodiment, but may refer to the same embodiment unless the context clearly dictates otherwise.
[0131] The term "and / or" or " / " means any one of the items, any combination of the items, or all of the items with which this term is associated.
[0132] The term "substantially" does not exclude "completely", e.g. a composition that is "substantially" free of Y may be completely free of Y. If desired, the term "substantially" may be omitted from the definition of the invention.
[0133] As used herein, the term "approximately" or "about" when applied to one or more values of interest refers to a value similar to the reference value mentioned. In some embodiments, the term "approximately" or "about" refers to a range of values that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the reference value mentioned in any direction (greater or less than), unless otherwise stated or clear from the context (except when such number exceeds 100% of the possible values). Unless otherwise indicated in the specification, the term "about" is intended to include values, e.g., weight percentages, close to the reference range that are equivalent in terms of the functionality of the individual components, compositions, or embodiments.
[0134] When values and ranges are provided herein, it should be understood that all values and ranges subsumed within those values and ranges are intended to be encompassed within the scope of the present invention. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the application.
[0135] As used herein, the term "each," when used in connection with a collection of items, is intended to identify each individual item in the collection, but does not necessarily refer to every item in the collection. Exceptions may occur where express disclosure or context clearly indicates otherwise.
[0136] Any and all examples provided herein, or the use of exemplary language (e.g., "such as"), are intended merely to better illustrate the invention and do not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. As used herein, the term "exemplary" is intended to mean "by way of example" and is not intended to indicate that any particular exemplary item is preferred or required.
[0137] All methods described herein may be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. For any of the methods provided, the method steps may occur simultaneously or sequentially. When method steps occur sequentially, the steps may occur in any order unless otherwise stated.
[0138] In cases where the method includes a combination of steps, unless otherwise stated herein, each and every combination or subcombination of the steps is encompassed within the scope of the disclosure.
[0139] Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it is not inconsistent with this disclosure. The publications disclosed herein are provided solely for their disclosure prior to the filing date of the present invention. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the publication dates provided may be different from the actual publication dates, which may need to be independently confirmed.
[0140] It will be understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof will be suggested to those skilled in the art and are to be included within the spirit and scope of the present application and the appended claims. EXAMPLES
[0141] Example 1 This example describes the materials and methods used in the subsequent examples below.
[0142] Ca v 1.1 Δe29 / ClC-1 - / - Generation of mouse strains Using CRISPR / Cas9, v 1.1 Δe29 / Δe29 Mice were generated. Exon 29 sequence was removed by targeting 50 nucleotides into the intronic sequence on either side of the intron / exon boundary. This ensured that both the exon and splice donor / acceptor sequences were removed. sgRNAs in this region were paired and completed with Cas9. The complex was injected into C57bl6 / J zygotes. Once they reached the blastocyst stage, the embryos were transferred into surrogate mice. This strain was then backcrossed to C57bl6 (Jackson) for over six generations to ensure the absence of off-target mutations. Removal of exon 29 was verified by RNA isolation of tibialis anterior muscle and Sanger sequencing of RT-PCR products between exons 27 (5'CCAGTCGGAACAGATGAACCAC (SEQ ID NO: 1)) and 31 (5'CCGATGACCGCGTAGATGAAGA (SEQ ID NO: 2)). Ca v 1.1 Δe29 / ClC-1 - / - To generate mice, we used Ca v 1.1 Δe29 / Δe29 Mice were used: adr-mto2J mice (Jackson Labs), which carry a frameshift mutation in the Clcn1 muscle-specific chloride channel that causes recessive generalized myotonia. Additionally, adr-mto2J mice were used throughout the experiments (ClC-1 - / - ). WT C57bl6 controls were obtained from Jackson Labs. All mice were housed, maintained, cared for, and studied in accordance with the approval of the University of Rochester Committee on Animal Resources.
[0143] Medicating mice with Verapamil Drugs were provided in Nutra-Gel Complete Nutrition (Bio-Serv) food cups to a final dose of 200 mg / kg / day of verapamil (V4629, (±)-verapamil hydrochloride, Sigma-Aldrich) in WT-treated control mice and Ca v 1.1 Δe29 / ClC-1 - / - Mice were treated. Immediately after weaning, mice were provided with a food cup and food was changed daily. No other food sources were provided, but water was provided with the cage and changed weekly.
[0144] Weight measurement Mice were weighed every other day from weaning until the end of the final experiment. For statistical analysis, a two-way ANOVA was performed on the average of each week's measurements. The percentage of weight change at 10 weeks was determined from the first weight measurement taken after weaning and the weight achieved at 10 weeks. A one-way ANOVA with multiple comparisons was performed on this data.
[0145] Systolic blood pressure and heart rate measurements: Systolic blood pressure and heart rate were measured using a non-invasive tail cuff BP-2000 blood pressure analysis system (Visitech Systems). Mice were allowed to acclimate to the testing room for 1 hour before the start of each day. 10-week-old WT mice treated with vehicle, 100 mg / kg / day, or 200 mg / kg / day were trained for 5 days to acclimate to the system. This was followed by 5 days of testing, starting immediately after the final training day. Throughout the training and testing, 10 preliminary measurements and 20 actual measurements were taken for each mouse.
[0146] Right reflex time Ca v 1.1 Δe29 / ClC-1 - / -To measure the effect of verapamil on muscle tone and strength in mice, righting reflex times were tracked weekly after the initiation of verapamil treatment. Mice were held in supine position on a horizontal surface and then released. Timing was started immediately after release by two individuals and stopped when all four paws were on the surface. This was repeated for a total of 10 righting responses, with a minimum of 5 minutes between each recording to avoid muscle tone warm-up. Records of less than 1 second were recorded as "1" and righting was considered a failure if it took more than 60 seconds to right. If failure was reached, no further records were measured for that mouse that week. The two longest and two shortest records for each mouse were removed and the mean of the middle 6 records was used for analysis. Two-way ANOVAs of weekly results and one-way ANOVAs with multiple comparisons of time point data (10 and 20 weeks) were performed.
[0147] Whole-body plethysmography Whole-body plethysmography (Buxco® Small Animal Whole Body Plethysmography, Data Science International) was used to measure the plethysmograms of the rats at 10 weeks (all groups) and 20 weeks (untreated Ca v 1.1 Δe29 / ClC-1 - / - Respiratory function was measured in a 10-min WBP chamber (excluding the 10-min WBP chamber). Mice were allowed to acclimate to the system for 2 days, and data were collected on the third day. For all three days, a single mouse was placed consciously and unrestrained in the WBP chamber and subjected to a 15-min acclimation period followed by 10-min data acquisition (Yonekawa T, et al. Science advances. 2022;8(21)). Mean data from the 10-min acquisition period for frequency (breaths / min) and ventilation (mL) were analyzed for statistics by one-way ANOVA with multiple comparisons.
[0148] Whole-cell patch clamp recordings of calcium currents from isolated adult FDB fibers Adult mice approximately 4 weeks after birth were sacrificed by cervical dislocation and decapitation as approved by the University Committee on Animal Resources at the University of Rochester. Isolated flexor digitorum brevis (FDB) muscle fibers for electrophysiology experiments were obtained by a previously described method (Lueck et al. J Gen Physiol. 2007 Jan;129(1):79-94). FDB muscles were immediately microdissected and immersed in standard electrophysiology Ringer's solution (146 mM NaCl, 5 KCl, 2 mM CaCl2, 1 mM MgCl2, and 10 mM HEPES, pH 7.4). The excised muscles were then digested in Ringer's solution supplemented with 2 mg / ml collagenase A (Roche, Mannheim, Germany) in a shaking water bath at 37°C for 1 h.
[0149] After enzymatic digestion, the muscles were mechanically dissociated by trituration with a flame-polished Pasteur pipette of decreasing pore size to obtain isolated single FDB fibers. The fibers were then plated on 35 mm plastic cell culture dishes for experiments. The fibers were stored at room temperature in Ringer's solution until utilized for experiments. All patch clamp experiments were completed within 8 hours of mouse sacrifice. To record Cav1.1 calcium currents using whole-cell patch clamp, solutions were designed to isolate calcium currents (TTX (Cayman Chemical Company, Ann Arbor, MI) was used to block sodium currents, TEA, 4-AP, and cesium were used to block potassium currents, and 9-AC was used to block chloride currents). The external recording solution contained 145 mM TEA-methanesulfonate, 10 mM CaCl2, 10 mM HEPES, 2 mM MgSO4, 1 mM 4-aminopyridine, 0.1 mM anthracene-9-carboxylic acid, and 0.001 mM tetrodotoxin with TEA-OH (pH 7.4). Low resistance pipettes were formed from thin-walled borosilicate glass using a Sutter P-97 puller (Sutter Instruments, Novato, CA) and flame-polished to a resistance of <1 MΩ. Pipettes were filled with the following internal solution: HEPES (pH 7.4) containing 140 mM Cs-aspartate, 10 mM Cs2-EGTA, 5 mM MgCl2, and 10 mM CsOH.
[0150] Healthy muscle fibers with well-defined striations were sealed to achieve a gigaseal with negative pressure, then whole-cell configuration was achieved by applying additional negative pressure that was maintained throughout data collection. Prior to collecting current recordings, fibers were maintained at a resting potential of -80 mV and hyperdialyzed for 15 min to allow the internal solution to equilibrate within the fiber. Currents were recorded with a standard voltage step protocol of 500 ms voltage steps from -50 to -80 to 80 mV at 10 mV intervals as described in Beqollari et al. (2015). Data were collected using an Axopatch 200b amplifier (Axon Instruments, San Jose, CA) and digitized with a Digidata 1550b (Axon Instruments). An AP / 4 online subtraction protocol was utilized to correct for linear components of leak and capacitive currents. Whole-cell parameters were adjusted and series resistance was compensated for (90%) to limit voltage errors. Recordings were sampled at 10 kHz and filtered at 2 kHz. Cell capacitance and other passive properties of muscle fibers were either obtained via Clampex 10 (Molecular Devices) or calculated based on the integration of 10-mV voltage steps from rest. Currents were normalized to fiber capacitance to obtain current density (pA / pF). All experiments were completed at room temperature. The peak current densities obtained for the voltage steps were plotted and fitted to the following equation to obtain IV curves: I=Gmax*(V-Vrev) / {1+exp[-(V-V1 / 2) / kG]}
[0151] In this equation, I corresponds to the peak current for a particular test potential normalized to cell capacitance, G is the maximal calcium conductance, V is the half-maximal activation potential, V is the reversal potential, and kG is the slope coefficient.
[0152] Histology and fiber classification For hematoxylin and eosin (H and E) staining and fiber classification by immunohistochemistry, tibialis anterior and diaphragm were isolated and snap frozen from 10- and 20-week-old mice (n=5 / group). Transverse 10-micron frozen sections from each muscle were collected on glass slides. For H and E, slides were immersed in hematoxylin for 3.5 min, followed by immersion once in ddH2O, 1% HCl, ddH2O, aqueous ammonia, ddH2O, and 5 min in eosin. Slides were dehydrated by two 30-second incubations in 95% ethanol, two 30-second incubations in 100% ethanol, and one 30-second incubation, followed by a 5-minute incubation in Hemo-De (xylene substitute). Slides were then mounted with Permount (Fisher) and imaged on an Olympus BX53. Immunohistochemistry to determine fiber type was performed as previously reported (Bachman JF, et al. Development. 2018;145(20) Epub 20181025). Briefly, slides were permeabilized once with PBST (PBS containing 0.2% Triton X-100) for 10 min, then blocked for 30 min in 10% normal goat serum (added later) at room temperature. Slides were then blocked for 60 min in 3% AffiniPure Fab Fragment anti-mouse IgG (H&L) (Jackson Immunoresearch) (0.1 mg / ml) containing 2% NGS in PBS at room temperature, then washed three times for 10 min each in PBS. Slides were incubated in primary antibodies (listed in Table B) for 14–18 h at 4°C. Slides were then washed three times for 10 min at room temperature in PBS, followed by addition of secondary antibodies (see Table B) and incubation for 60 min. After another set of three washes for 10 min in 1× PBS at room temperature, slides were mounted with Fluromount-G (Invitrogen). Slides were imaged using a Keyance BZ-X810 All-in-One Fluorescence Microscope (Leica).
[0153] In vitro muscle contraction Muscle strength and frequency dependence were measured by in vitro muscle contractions performed on an Aurora Scientific 1200A in vitro system equipped with an 809B muscle testing system with a 300C-LR force transducer and a 701C stimulator (Aurora Scientific). v 1.1 Δe29 , ClC-1 - / - , untreated Ca v 1.1 Δe29 / ClC-1 - / - (only at 10 weeks), and Ca v 1.1 Δe29 / ClC-1 - / - + verapamil mice were used. Mice were anesthetized with 2% inhaled isoflurane. For the EDL muscle, the proximal and distal tendons of the EDL were exposed after removing the tibialis anterior muscle and tied off using sutures. The proximal tendons were fixed to a fixed post and the distal tendons were fastened to a force transducer. For the diaphragm, a 4 mm piece was cut from the right rib hemidiaphragm as described in Hakim, C. et al. (2019). Sutures were used to connect the diaphragm piece from the rib to the fixed post and the central tendon was fastened to the force transducer (Hakim CH, et al., Sci Rep. 2019;9(1):19453). For both muscle groups, the muscles were anesthetized with warmed (30°C) and oxygenated (95% O2 and 5% CO2) Ringer's buffer (1.2 mM NaH2PO4, 0 ... 4、 The solution was immersed between platinum electrodes in a pH 7.4 (Hakim CH, et al. Methods Mol Biol. 2011;709:75-89) containing 1 mM MgSO4, 4.83 mM KCl, 137 mM NaCl, 2 mM CaCl2, 10 mM glucose, 24 mM NaHCO3, pH 7.4). The optimal length (L o The EDL and diaphragm muscles were allowed to equilibrate for 10 min before determining the maximum output (120% stimulation voltage) and supramaximal output (120% stimulation voltage).
[0154] The muscles were then subjected to a twitch warm-up protocol (three 200 ms 1 Hz stimuli spaced 20 seconds apart) and a tetanic warm-up protocol (three 500 ms, 150 Hz stimuli spaced 1 minute apart) before frequency dependence was determined. Frequency dependence was determined with increasing 500 ms stimuli spaced 1 minute apart unless otherwise stated. For the EDL, the stimuli were as follows: 1 Hz (200 ms), 25 Hz, 50 Hz, 75 Hz, 100 Hz, 125 Hz, 150 Hz, 175 Hz, 200 Hz, and 250 Hz. For the diaphragm, the stimuli were 1 Hz (200 ms), 10 Hz, 20 Hz, 40 Hz, 60 Hz, 80 Hz, 100 Hz, 125 Hz, 150 Hz, and 200 Hz. Muscle force was recorded using 610A Dynamic Muscle Control LabBook software (Aurora Scientific) and analyzed using Clampfit 10.0 software. Specific force was calculated using muscle wet weight and optimized length between proximal and distal muscle-tendon junctions (Hakim CH, et al. Methods Mol Biol. 2011;709:75-89, and Hakim CH, et al. J Vis Exp. 2013(72)). Two-way ANOVA analysis was used to determine statistical differences between groups for frequency dependence.
[0155] muscle tone Muscle tone was measured using in vitro muscle contraction. EDLs were cultured at 20 weeks WT and Ca v 1.1 Δe29 Muscles were isolated from mice and optimized as in the previous section. To obtain a baseline of muscle tone free, muscles were equilibrated for 25 min in Ringer's medium. Muscles were then subjected to a protocol to determine muscle tone with three consecutive 200 ms 1 Hz twitches separated by 20 s, a 3 min rest period, and then three consecutive 500 ms 150 Hz tetanic contractions separated by 3 min. Ringer's medium containing 100 uM 9-acridine carboxylic acid (9-AC) was flushed into the bath for 25 min, and the muscle tone protocol was repeated. This timing was to allow sufficient time for buffer exchange and for the muscle to equilibrate in the new bath. WT and Ca v 1.1Δe29 To determine the effect of verapamil on muscle tone in muscles, the muscle tone protocol (described earlier in this section) was performed in the presence of Ringer's medium containing either 5 μM or 20 μM verapamil, followed by Ringer's medium containing 100 μM 9-AC and either 5 μM or 20 μM 9-AC. Muscle forces were recorded using 610A Dynamic Muscle Control LabBook software (Aurora Scientific) and traces were analyzed using Clampfit 10.0 software to calculate the area under the curve. The area under the curve was then normalized to specific force (calculated as in the previous section) and used for statistical analysis.
[0156] Transient weakness Transient weakness was measured in EDL muscles by in vitro muscle contraction. EDLs were cultured in 20-week-old WT or Ca2+ mice, as described in the previous section. v 1.1 Δe29 Muscles were isolated and optimized from mice. Experiments were contralaterally conditioned with one side equilibrated in normal Ringer's medium and the other side in Ringer's medium containing 100 μM 9-AC for at least 25 min. The muscles were then subjected to a transient weakness protocol of 45 consecutive 500 ms 100 Hz tetanic contractions spaced 4 s apart. To determine the effect of different calcium channel blockers on transient weakness, drugs were delivered via Ringer's medium in a contralateral manner where one side received drug only and the other drug + 9-AC. The calcium channel blockers tested were verapamil at both 5 μM and 20 μM concentrations, nifedipine at 75 nM, amlodipine at 10 μM, and diltiazem at 10 μM. For all drugs tested, the muscles were equilibrated in the drug-containing medium for 25 min before performing the transient weakness protocol. Muscle forces were recorded and analyzed as in the previous section. Specific forces were calculated and the ratio of the initial forces generated was also examined for statistical analysis.
[0157] statistical analysis All data mean data are presented as mean ± SEM, represented either as bars with error bars or filled circles with error bands. Data points collected for a single mouse were represented as open circles (one mouse is n=1). However, for in vitro muscle contraction techniques, open circles represent one muscle (one muscle is n=1). The number of sampled units for which statistics were reported, n, is a single mouse for in vivo experiments (one mouse is n=1). GraphPad Prism 9 software was used for statistical analysis. One-way or two-way ANOVA with multiple comparisons was used to test for significant differences between each of the groups tested. For survival, each group was compared with the Kaplan-Meier log-rank test of each other group. For all figures, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 were used.
[0158] Example 2 As shown in Figure 1, Ca V 1.1 Δe29 and ClC-1 - / - The allele is synthetically lethal, resulting in significant weight loss and severe muscle weakness in mice. v 1.1 Δe29 / + (n=13), Ca v 1.1 Δe29 (n=15), ClC -1- / - (n=40), Ca v 1.1 Δe29 / + / ClC -1- / - (n=16), and Ca v 1.1 Δe29 / Δe29 / ClC -1- / - The results of Kaplan-Meier survival analysis of (n=21) are shown. v 1.1 Δe29 / + / ClC-1 - / - and Ca v 1.1 Δe29 / Δe29 / ClC-1 - / - The survival of both ClC-1 and ClC-2 mice is significantly reduced compared to WT mice. - / - The levels of Ca were significantly lower than those of mice treated with CaCl alone. v 1.1 Δe29 / + / ClC-1 - / - and Ca v 1.1 Δe29 / Δe29 / ClC-1 - / - Mice did not survive beyond 14 weeks of age, with both having a median life expectancy of 9.8 and 8.1 weeks, respectively. Figure 1B shows the results of weekly weight analysis. Figure 1C shows the percentage weight change from weaning at 10 weeks. Together, Figures 1B-C show the effect of Ca v 1.1 Δe29 / ClC-1 - / - The results show that mice with Ca2+ / Ca ... v 1.1 Δe29 / ClC-1 - / - The weekly weight and weight change rate of mice were measured using ClC-1. - / - Figure 1D shows representative specific force traces, and Figure 1E shows the average peak specific force evoked by 150 Hz (500 ms) tetanic stimulation of isolated EDL muscles from 10-week-old mice. Figure 1F shows the average frequency-dependence of specific force generation evoked from isolated EDL muscles from 10-week-old mice. v 1.1 Δe29 / ClC-1 - / - The EDL muscle, which is a Ca2+-dependent vasculitis, is very weak. Symbols, open circles, individual mice; bars and closed circles, mean ± SEM. Taken together from Figures 1D, 1E, and 1F, the Ca2+-dependent vasculitis in the EDL muscle is very weak. v 1.1 Δe29 / ClC-1 - / - Mice show a marked lack of force generation compared to WT muscles.
[0159] Next, Ca v 1.1 Δe29 / ClC-1 - / - The effect of verapamil in increasing survival, body weight, and muscle function in mice was investigated. As shown in Figure 2, verapamil treatment reduced Ca v 1.1 Δe29 / ClC-1 - / - Improves survival, body weight, and muscle function in mice. Figure 2A shows the results of the treatment with WT + vehicle (n = 10), WT + 200 mg / kg / day verapamil (n = 10), Ca v 1.1 Δe29 / ClC- 1 - / - (n=37), and Ca v 1.1 Δe29 / Δe29 / ClC - 1 - / - + Verapamil (n=9) results of Kaplan-Meier survival analysis. Verapamil is administered in the nutrition / hydration food cup of mice. This panel found that treatment with 200 mg / kg / day of verapamil reduced Ca v 1.1 Δe29 / ClC-1 - / - Significantly improves the lifespan of mice. For mice that survived the time course of the survival study, the final experiment was completed after 20 weeks of age. v 1.1 Δe29 / ClC-1 - / - Mice life span was significantly longer than untreated Ca v 1.1 Δe29 / ClC-1 - / - The effect of verapamil on the development of pulmonary circulation was significantly increased and remained robust compared to control rats. Figure 2B shows the results of body weight analysis. v 1.1 Δe29 / ClC-1 - / - Mice were treated with untreated Ca v 1.1 Δe29 / ClC-1 - / - Verapamil treatment in WT mice did not significantly affect body weight, indicating that verapamil treatment is safe for use in WT mice. Figures 2C and 2E show representative specific force traces evoked by twitch (left) and 150 Hz (500 ms) tetanic (right) stimulation of EDL muscles isolated from 10-week (Figure 2C) and 20-week (Figure 2E) mice. Figures 2D and 2F show plots of the mean stimulation frequency dependence of specific force generation from isolated EDL muscles at 10 weeks of age (Figure 2D) and 20 weeks of age (Figure 2F) in the indicated genotypes and treatment groups. From the in vitro muscle contraction data presented in Figures 2C-D, verapamil-treated Ca2+ mice showed significantly greater increases in specific force compared to untreated mice. v 1.1 Δe29 / ClC-1 - / -There is a significant improvement in force production at 10 weeks in the EDL muscle. This is due to the myoprotective effect of verapamil treatment, as these experiments are performed without verapamil in the bath. Therefore, the improvement seen at this age is due to long-term verapamil treatment. v 1.1 Δe29 / ClC-1 - / - Early death of mice was due to verapamil-treated Ca v 1.1 Δe29 / ClC-1 - / - For mice, no direct comparisons can be made at week 20. Symbols, filled circles, mean±SEM.
[0160] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - The effect of verapamil in improving righting reflex time in mice was also investigated. As shown in Figure 3, verapamil treatment reduced ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - The righting reflex time in mice was significantly improved. v 1.1 Δe29 / ClC-1 - / - , ClC-1 - / - , Ca v 1.1 Δe29 , W.T., Ca v 1.1 Δe29 / ClC-1 - / - Figure 3B shows the results of weekly righting reflex time analysis of WT + Verapamil and WT + Verapamil mice, and Figure 3B shows the average righting reflex time in 10- and 20-week-old vehicle- and verapamil-treated mice. v 1.1 Δe29 / ClC-1 - / - Since mice do not survive to 20 weeks of age, the last recording before death is documented. Boxes represent Q1, median, and Q3; whiskers indicate minimum and maximum values. From Figures 3A and 3B, untreated and verapamil-treated Ca v 1.1 Δe29 / ClC-1 - / -The positive relaxation time was significantly reduced when compared to untreated Ca mice. v 1.1 Δe29 / ClC-1 - / - As mice age, they become unable to do this (taking more than 60 seconds to right themselves). - / - The verapamil-treated Ca v 1.1 Δe29 / ClC-1 - / - In mice, not only is the righting time significantly reduced, but it also maintains a consistent righting time with age. v 1.1 Δe29 / ClC-1 - / - The improvement in righting latency seen in mice was such that there was no significant difference in righting latency compared to WT mice, which righted in less than 1 second (recorded as "1"). Figure 3C shows the effect of ClC-1 at doses of 100 mg / kg / day (left) and 200 mg / kg / day (right) in the nutrition / hydration food cup. - / - Paired mice are shown before (light circles) and after (dark circles) 2 weeks of verapamil treatment. ClC-1− / − alone mice show significantly lower levels of WT Ca v 1.1, verapamil was able to significantly reduce the righting time for both dosages tested in these paired experiments, indicating that verapamil is a potential treatment for congenital myotonia. Symbols, filled circles, individual mice; open circles, mean ± SEM.
[0161] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - We investigated the effect of verapamil in improving respiratory function and diaphragm strength in mice. As shown in Figure 4, verapamil treatment reduced Ca v 1.1 Δe29 / ClC-1 - / -Verapamil significantly improves respiratory function and diaphragm strength in mice. Whole-body plethysmography of 10-week-old (Figures 4A and 4C) and 20-week-old (Figures 4B and 4D) mice of the indicated genotypes and treatment groups. Figures 4A and 4B show respiratory frequency (breaths / min), and Figures 4C and 4D show respiratory volume (mL). Overall, verapamil-treated Ca v 1.1 Δe29 / ClC-1 - / - Mice showed no significant difference in frequency or ventilation volume at 20 weeks. At 10 weeks, compared to untreated, v 1.1 Δe29 / ClC-1 - / - Verapamil treatment in mice significantly improves ventilation. v 1.1 Δe29 / ClC-1 - / - Ventilation in mice returns to that of WT mice at 10 weeks. Figure 4E shows representative tetanic (150 Hz, 500 ms) specific force traces from diaphragm strips isolated from 10-week-old (left) and 20-week-old (right) mice in the indicated genotypes and treatment groups. Figures 4F and 4G show plots of the mean stimulation frequency dependence of specific force generated from diaphragm strips isolated from 10-week-old (Figure 4F) and 20-week-old (Figure 4G) mice in the indicated genotypes and treatment groups. Figures 4E, 4F, and 4G show that verapamil-treated Ca2+-treated mice showed a significantly increased tetanic (150 Hz, 500 ms) specific force traces from diaphragm strips isolated from 10-week-old (Figure 4F) and 20-week-old (Figure 4G) mice in the indicated genotypes and treatment groups. v 1.1 Δe29 / ClC-1 - / - The force and frequency dependence of diaphragm strip muscle in mice is significantly improved. Verapamil treatment significantly improved Ca v 1.1 Δe29 / ClC-1 - / - Mice show WT intensity in their diaphragm strips at both 10 and 20 weeks. Furthermore, the frequency-dependent improvement seen at 10 weeks was greater in untreated and treated Ca2+ mice. v 1.1 Δe29 / ClC-1 - / - Correlating the construction data with the plethysmography data shown in this figure, the Ca v 1.1 Δe29 / ClC-1 - / -There is a general deficit in respiratory function in the mice, which is significantly improved by verapamil treatment. Symbols, open circles, individual mice; bars and closed circles, mean ± SEM. Note: Untreated Ca v 1.1 Δe29 / ClC-1 - / - Mice do not survive to 20 weeks of age.
[0162] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - We investigated the effect of verapamil in improving severe transient muscle weakness in mice. As shown in Figure 5, Ca v 1.1 Δe29 / ClC-1 - / - Muscles show severe transient weakness that is significantly ameliorated by the addition of verapamil. Figures 5A and 5C show the effect of 6-week ClC-1 in the absence of verapamil (Figure 5A) and in the presence of 20 μM verapamil added to the bath (Figure 5C). - / - and Ca v 1.1 Δe29 / ClC-1 - / - Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDL isolated from a mouse. - / - (n=4) and Ca v 1.1 Δe29 / ClC-1 - / - In the presence of 20 μM verapamil added to the bath of the EDL (Figure 5D), 6-week-old WT (n=4), ClC-1 - / - (n=4), Ca v 1.1 Δe29 (n=4), and Ca v 1.1 Δe29 / ClC-1 - / - Figure 5D shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from one mouse (n=4, 100 Hz, 100 ms ... v 1.1Δe29 / ClC-1 - / - This shows that there is a transient weakness in the EDL muscle. The transient weakness seen is due to ClC-1 - / - This is more severe than the EDL muscle alone. Verapamil treatment reduces ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - There is a marked improvement in transient weakness in both the EDL muscles of the hamster and the hamster. The presence of verapamil in the bath reduces ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - Both treatments reduced force weakness in the EDL muscle and there was a significant improvement in recovery from transient weakness, symbols, filled circles, mean ± SEM.
[0163] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - We investigated the effect of verapamil in reducing muscle tone in mice. As shown in Figure 6, verapamil reduced the Ca v 1.1 Δe29 / ClC-1 - / - and ClC-1 - / - Figures 6A and 6C show the effect of verapamil on muscle tone in 6-week WT and Ca mice in the absence of verapamil (Figure 6A) and in the presence of 20 mM verapamil added to the bath (Figure 6C). v 1.1 Δe29 Representative normalized specific force traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) from EDLs isolated from mice. Dashed lines represent accumulated force. Figures 6B and 6D show the cumulative force in WT and Ca mice over three tetanic stimuli (150 Hz, 500 ms) in the absence of verapamil (Figure 6B) and in the presence of 20 mM verapamil added to the bath (Figure 6D). v 1.1 Δe29 Figures 6E and 6G show the mean normalized integral of EDL force. - / - and Ca v 1.1Δe29 / ClC-1 - / - Representative normalized specific force traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) from EDL isolated from a mouse. The dashed lines represent the accumulated force. Figures 6F and 6H show the force profiles of ClC-1 over three tetanic stimuli (150 Hz, 500 ms) in the absence of verapamil (Figure 6B) and in the presence of 20 mM verapamil added to the bath (Figure 6D). - / - and Ca v 1.1 Δe29 / ClC-1 - / - The mean integral of the force across the EDL is shown. Overall, this figure shows that Ca v 1.1 Δe29 The presence of ClC-1 - / - The presence of verapamil in the bath significantly prolongs muscle tone in vitro compared to that seen in isolated muscles. - / - and Ca v 1.1 Δe29 / ClC-1 - / - The effect of stimulating the EDL muscle on the skeletal muscle was significantly reduced in both the untreated and treated EDL muscles. Symbols, open circles, individual mice; bars, mean ± SEM. The contralateral EDL was used for each untreated and treated experiment. All traces were plotted on the same time scale and normalized force for comparison.
[0164] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - We investigated the effect of verapamil in rescuing force production in the EDL muscle in mice. As shown in Figure 7, Ca v 1.1 Δe29 / ClC-1 - / - Long-term oral feeding of mice with verapamil significantly rescues force production in EDL muscles. Mean peak specific force evoked using 150 Hz (500 ms) tetanic stimulation of EDLs isolated from 10-week (Figure 7A) and 20-week (Figure 7B) mice of the indicated genotypes and treatments. At 10 weeks, untreated Ca v 1.1 Δe29 / ClC-1 - / -Muscles show a significant lack of force production at 10 weeks. Compared to untreated, Ca treated v 1.1 Δe29 / ClC-1 - / - Force production in the EDL muscle is significantly improved. The improvement seen is hypothesized to be a myoprotective effect of verapamil treatment since verapamil is not present in the bath at the time of the experiment. Symbols, open circles, individual mice; bars, mean ± SEM.
[0165] ClC-1 - / - and Ca v 1.1 Δe29 / ClC-1 - / - We investigated the effect of verapamil in rescuing diaphragm muscle force production in mice with Ca. v 1.1 Δe29 / ClC-1 - / - Long-term oral feeding of verapamil to mice significantly rescues diaphragm muscle force production. Mean peak specific forces evoked using 150 Hz (500 ms) tetanic stimulation of diaphragm strips isolated from 10-week (Figure 8A) and 20-week (Figure 8B) mice of the indicated genotypes and treatments. At 10 weeks, untreated Ca v 1.1 Δe29 / ClC-1 - / - Diaphragm muscles showed a significant lack of force generation at 10 weeks. Compared to untreated, treated Ca v 1.1 Δe29 / ClC-1 - / - Force production in the diaphragm strips is significantly improved. The improvement seen is due to the myoprotective effect of verapamil treatment, since verapamil is not present in the bath at the time of the experiment. This rescue of force production by verapamil is due to the fact that the treated Ca v 1.1 Δe29 / ClC-1 - / - There is no significant difference between diaphragm strips and WT. This improvement is maintained at 20 weeks of age. Symbols, open circles, individual mice; bars, mean ± SEM.
[0166] 9A, 9B, 9C, and 9D are a series of graphs showing the results of quantification and statistical analysis of fiber type distribution in the tibialis anterior muscle. Quantification of type IIb (FIG. 9A), type IIx (FIG. 9B), type IIa (FIG. 9C), and type I (FIG. 9D) fibers in the tibialis anterior muscle (n=5 / group) at 10 weeks (left) and 20 weeks (right) is shown. v 1.1 Δe29 / ClC-1 - / - Fiber type distribution in the tibialis anterior muscle was ClC-1 at both 10 and 20 weeks of age. - / - This is dominated by the phenotypic changes seen due to the presence of
[0167] 10A, 10B, 10C, and 10D are a series of graphs showing the results of quantification and statistical analysis of fiber type distribution in diaphragm muscle. Quantification of type IIb (FIG. 10A), type IIx (FIG. 10B), type IIa (FIG. 10C), and type I (FIG. 10D) fibers in 10-week (left) and 20-week (right) diaphragm muscles (n=5 / group) is shown. v 1.1 Δe29 / ClC-1 - / - The fiber type distribution of the diaphragm was ClC-1 at both 10 and 20 weeks of age. - / - This is dominated by the phenotypic changes seen due to the presence of
[0168] 11A, 11B, and 11C show heterozygous and homozygous Ca v 1.1 Δe29 Mice have similar Ca in the flexor digitorum brevis muscle. v 1.1 A series of graphs showing voltage dependence and peak current density. v 1.1 Δe29 / + (dashed line), and Ca v 1.1 Δe29 / Δe29 Figure 11B shows representative current density traces from whole-cell patch clamp of flexor digitorum brevis fibers isolated from WT, Ca (solid line) and WT, Ca (solid line) mice at 0 mV (top), +20 mV (middle), and +40 mV (bottom). v 1.1 Δe29 / + (circle, dashed line), and Ca v 1.1 Δe29 / Δe29 (Circles, solid line) Ca measured in flexor digitorum brevis fibersv 1.1 shows plots of the average current-voltage relationship of activity. v Figure 11C shows that heterozygous loss of exon 29 in 1.1 has nearly the same current density and current-voltage relationship as homozygous loss of exon 29. v 1.1 RT-PCR products of RNA PCR amplification from exons 27–31 of Caca1ns cDNA.
[0169] 12A, 12B, 12C, and 12D show Ca v 1.1 Δe29 / ClC-1 - / - 12A and 12C are a series of graphs (not normalized to the first peak force) showing that the muscle shows severe transient weakness that is significantly ameliorated by the addition of verapamil. - / - and Ca v 1.1 Δe29 / ClC-1 - / - Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from the EDL isolated from a ClC-1 mouse. - / - (n=4) and Ca v 1.1 Δe29 / ClC-1 - / - WT (n=4), ClC-1 (n=4), and EDL (n=4) at 6 weeks of age in the absence of verapamil (Fig. 12B) and in the presence of 20 μM verapamil added to the bath (Fig. 12D). - / - (n=4), Ca v 1.1 Δe29 (n=4), and Ca v 1.1 Δe29 / ClC-1 - / -Figure 12D shows plots of the average peak tetanic EDL evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from one mouse (n=4). The dashed line in Figure 12D represents the average data presented in Figure 12B as a pre-treatment reference. The findings in this figure are similar to Figure 5. This figure shows that Ca2+ levels were significantly improved by verapamil treatment. v 1.1 Δe29 / ClC-1 - / - Further exacerbating the severe transient weakness seen in the EDL muscle. Symbols, filled circles, mean ± SEM.
[0170] 13A, 13B, 13C, 13D, 13E, 13F, 13G, and 13H show that verapamil treatment reduces the expression of WT, Ca v 1.1 Δe29 、 ClC-1 - / - 、 and Ca v 1.1 Δe29 / ClC-1 - / - 13A, 13C, 13E, and 13G are a series of graphs showing that verapamil does not reduce peak contractile force in mouse muscles. v 1.1 Δe29 (Figure 13C), ClC-1 - / - (Figure 13E), and Ca v 1.1 Δe29 / ClC-1 - / - Representative traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL in (Fig. 13G). Treatments are indicated in the legend. Figs. 13B, 13D, 13F, and 13H show the results of three tetanic stimulations in the absence and presence of 20 mM verapamil for WT (Fig. 13B), Ca v 1.1 Δe29 (Fig. 13D), ClC-1 - / - (Figure 13F), and Ca v 1.1 Δe29 / ClC-1 - / -(FIG. 13H) shows the average specific force of the EDL. Treatments are indicated in the legend. This experiment was performed to show that the presence of verapamil in the bath does not affect the specific force production of the EDL muscle for any of the groups tested. Symbols, open circles, individual mice; bars, mean and SEM.
[0171] Figures 14A and 14B show that verapamil inhibits Ca v 1.1 Δe29 / ClC-1 - / - and ClC-1 - / - FIG. 14A is a series of graphs showing that ClC-1 in the absence of 20 μM verapamil significantly reduces muscle tone in both mouse muscles. - / - (solid line) and Ca v 1.1 Δe29 / ClC-1 - / - Representative traces of normalized specific force production of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL in (solid line). The dashed line represents the accumulated force. Figure 14B shows the effect of ClC-1 in the presence of 20 μM verapamil. - / - (solid line) and Ca v 1.1 Δe29 / ClC-1 - / - Representative traces of the first (left) and third (right) tetanic contractions (150 Hz, 500 ms) in the EDL in (solid lines). The dashed line represents the accumulated force. Note: The traces shown in Figure 6 are replotted here on an expanded time scale to better observe muscle tone. The findings described in the Figure 6 section are further substantiated by this alternative presentation.
[0172] 15A, 15B, 15C, 15D, 15E, and 15F show the Ca v 1.1 Δe29 FIG. 15A is a series of graphs showing that Ca exacerbates transient weakness in myotonic muscles and is alleviated by verapamil. FIG. 15B is a series of graphs showing that Ca exacerbates transient weakness in myotonic muscles and is alleviated by verapamil. v 1.1 Δe29Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 s apart, recorded ex vivo from an isolated EDL from a mouse are shown. v Absence of exon 29 in 1.1 aggravates transient weakness of myotonic EDL. v 1.1 Δe29 (n=5), and Ca v 1.1 Δe29 Plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from each other from +9-AC (n=5) mice are shown. The right myotonic WT EDL muscle underwent mild transient weakness that quickly recovered. v 1.1 Δe29 There was a significant initial force depression in the +9AC EDL, and recovery from this transient weakness required multiple stimuli. Figures 15C and 15E show the effect of 100 mM 9-AC and 5 mM verapamil (Figure 15C) or 20 mM verapamil (Figure 15E) on the 20-week WT and +9AC EDL. v 1.1 Δe29 Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 s apart, recorded ex vivo from EDLs isolated from mice. D shows the force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 s apart, recorded ex vivo from EDLs isolated from mice. E and F show the force traces of the first 15 tetanic contractions (100 Hz, 500 ms), spaced 4 s apart, recorded ex vivo from EDLs isolated from mice. D shows the force traces of the first 15 tetanic contractions (100 Hz, 500 ms), spaced 4 s apart, recorded ex vivo from EDLs isolated from mice. v 1.1 Δe29 + 5 mM verapamil (n=5), and Ca v 1.1 Δe29 Figure 15F shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from EDLs in WT + 20 mM verapamil (n = 5), WT + 9-AC + 20 mM verapamil (n = 5), Ca v 1.1 Δe29 + 20 mM verapamil (n=5), and Ca v 1.1 Δe29Figure 15 shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100Hz, 500ms tetanic stimuli spaced 4 seconds apart from EDLs in +9-AC+20mM Verapamil (n=5). The dashed lines in Figures 15D and 15F represent the average data presented in Figure 15B as a pre-treatment reference. Overall, both 5um and 20um Verapamil reduced the EDL force of WT+9-AC and Ca v 1.1 Δe29 +9-AC improves the transient weakness of EDL muscle. This improvement was observed in the presence of 20μm Ca v 1.1 Δe29 Significant and robust against +9-AC. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used.
[0173] Figures 16A and 16B show that transient weakness in WT and Ca v 1.1 Δe29 FIG. 16 is a series of graphs showing that WT and Ca2+-deficient muscle at 20 weeks are not affected by Ca2+-deficient muscle. v 1.1 Δe29 Figure 16B shows a representative trace of the first 15 tetanic contractions (150 Hz, 500 ms) spaced 4 s apart in the EDL muscle of 20-week WT and v 1.1 Δe29 Figure 1 shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from EDLs isolated from mice. Symbols, filled circles, mean ± SEM.
[0174] 17A, 17B, 17C, 17D, 17E, and 17F show the Ca v 1.1 Δe29 Figures 17A, 17B, and 17C (left) are a series of graphs showing that verapamil significantly worsens muscle tone in 20-week WT and Ca mice in the absence (pre-treatment) (Figure 17A, left) and in the presence (pre-treatment) of 5 mM (Figure 17B, left) and 20 mM (Figure 17C, left) verapamil added to the bath. v 1.1 Δe29Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from mice. Dashed lines represent cumulative force production. Figures 17A, 17B, and 17C (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 17D, 17E, and 17F (left) show the results of the normalization of force traces of 20-week WT and Ca mice incubated with 100 mM 9-AC in the absence (pre-treatment) of verapamil (Figure 17D, left) and in the presence (pre-treatment) of 5 mM (Figure 17E, left) and 20 mM (Figure 17F, left) verapamil added to the bath. v 1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from mice are shown. The dashed lines represent the cumulative force production. Figures 17D, 17E, and 17F (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used.
[0175] Figures 18A, 18B, 18C, 18D, 18E, and 18F show that verapamil treatment reduces the cellular cellular fate of non-myotonic and myotonic WT and Ca v 1.1 Δe29 18A-C are a series of graphs showing that 20-week WT and Ca2+ do not reduce peak contractile force in mouse muscles in the absence (pre-treatment) (FIG. 18A, left) and in the presence (pre-treatment) of 5 mM (FIG. 18B, left) and 20 mM (FIG. 18C, left) verapamil added to the bath. v 1.1 Δe29Representative specific force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDL isolated from 20-week-old WT and Ca mice. The dashed line represents the cumulative force production. Figures 18A, 18B, and 18C (right) show plots of the average integral of the specific force shown in the respective left panels. Figures 18D, 18E, and 18F (left) show plots of the average integral of the specific force shown in the respective left panels after incubation with 100 mM 9-AC in the absence (pre-treatment) of verapamil (Figure 18D, left) and in the presence (pre-treatment) of 5 mM (Figure 18E, left) and 20 mM (Figure 18F, left) verapamil added to the bath. v 1.1 Δe29 Representative specific force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from mice are shown. The dashed line represents the cumulative force production. Figures 18D, 18E, and 18F (right) show plots of the average integral of the specific forces shown in the respective left panels. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used.
[0176] This example also provides the effect of amlodipine in a mouse model. As shown in FIG. V 1.1 De29 and ClC-1 - / - The allele is synthetically lethal, resulting in significant weight loss and severe muscle weakness in mice. Amlodipine treatment significantly improved survival and weight change rates. Figure 19A shows the results of the WT (n=10), Ca v 1.1 Δe29 / + (n=13), Ca v 1.1 Δe29 (n=15), ClC-1 - / - (n=40), Ca v 1.1 Δe29 / + / ClC-1 - / - (n=16), Ca v 1.1 Δe29 / Δe29 / ClC-1 - / - (n=21), and Ca v 1.1 Δe29The results of Kaplan-Meier survival analysis of untreated Ca + ClC-1 + 5 mg / kg / day amlodipine (n=6) are shown. v 1.1 Δe29 / + / ClC-1 - / - and Ca v 1.1 Δe29 / Δe29 / ClC-1 - / - Mice with Ca2+ had a significantly reduced life span; 14 weeks was the longest survival time reached by mice, with a median life expectancy of only 8.9 weeks. v 1.1 Δe29 / ClC-1 - / - Mice had significantly improved survival. Figure 19B shows the percent weight change from weaning at 10 weeks. v 1.1 Δe29 / ClC-1 - / - Mice fail to thrive and exhibit body weights significantly reduced from those of WT mice, which is due to the ClC-1 - / - There was no significant difference in the weight change rate from that of single mice. Nevertheless, treatment with 5 mg / kg / day of amlodipine reduced the Ca v 1.1 Δe29 / ClC-1 - / - The treatment improved the rate of weight change in mice, which was a marked improvement compared to untreated mice. The change in weight gain with treatment was not significantly different from WT. Symbols, open circles, individual mice; bars and filled circles, mean ± SEM.
[0177] Ca v 1.1 Δe29 / ClC-1 - / - The effect of amlodipine in improving righting reflex time in mice was also investigated. As shown in Figure 20, amlodipine treatment significantly improved Ca2+ levels compared to untreated mice. v 1.1 Δe29 / ClC-1 - / - The righting reflex time in mice was significantly improved. v 1.1 Δe29 / ClC-1 - / - , ClC-1 - / - , Ca v 1.1 Δe29 , W.T., Ca v 1.1 Δe29 / ClC-1 - / - + Weekly righting reflex time analysis of amlodipine (purple) mice. v 1.1 Δe29 / ClC-1 - / - Mice have a significantly longer righting reflex time. As they age, the time to right increases until they are unable to right themselves, which is when the mice take more than 60 seconds to right themselves. v 1.1 Δe29 / ClC-1 - / - Treatment with 5 mg / kg / day amlodipine in mice significantly improved righting time. - / - Compared to mice alone, treated with Ca v 1.1 Δe29 / ClC-1 - / - There is no significant difference in righting in mice. Figure 20B shows the mean righting reflex time in vehicle- and amlodipine-treated mice at 10 and 20 weeks of age. The data show that Ca v 1.1 Δe29 / ClC-1 - / - The mice were WT mice and ClC-1 - / - The mice further showed that they had a significantly longer righting time compared to the control mice. Treatment with 5 mg / kg / day amlodipine was superior to untreated Ca2+ mice. v 1.1 Δe29 / ClC-1 - / - Compared with mice, Ca v 1.1 Δe29 / ClC-1 - / - This improvement in mean righting time was due to the fact that the treated Ca v 1.1 Δe29 / ClC-1 - / - There was no significant difference in the time to righting between untreated and WT mice. v 1.1 Δe29 / ClC-1 - / - Mice do not survive to 20 weeks of age, so the last reading before death is documented. Boxes represent Q1, median, and Q3; whiskers indicate minimum and maximum values. Symbols, filled circles, individual mice; open circles, mean ± SEM.
[0178] Next, Ca v 1.1 Δe29 / ClC-1 - / - The effect of amlodipine in improving breathing in mice was investigated. As shown in Figure 21, Ca v 1.1 Δe29 / ClC-1 - / - Mice showed altered respiration compared to WT and were treated with amlodipine, which reduced Ca v 1.1 Δe29 / ClC-1 - / - Mice do not have significantly different frequency or minute ventilation compared to WT. Whole-body plethysmography of 10-week (left) and 20-week (right) mice of the indicated genotypes and treatment groups. Respiratory frequency (breaths / min) (Figure 21A), respiratory ventilation (mL) (Figure 21B), and minute ventilation (Figure 21C) are shown. At 10 weeks, Ca v 1.1 Δe29 / ClC-1 - / - The frequency of Ca2+ / Ca2+-induced leukemia was significantly increased in the WT mice compared to the WT mice. v 1.1 Δe29 / ClC-1 - / - Treatment with 5 mg / kg / day amlodipine in mice reduced the frequency of Ca v 1.1 Δe29 / ClC-1 - / - There was no significant difference in frequency compared to WT mice, and no significant difference when compared to WT mice. This may be due to the moderate effect of amlodipine treatment on frequency. Ventilation and minute ventilation in 10-week treated mice were significantly higher than in untreated Ca mice. v 1.1 Δe29 / ClC-1 - / - The results are not improved compared to mice at 20 weeks of age. v 1.1 Δe29 / ClC-1 - / - The frequency of Ca in mice is not significantly different from that in WT mice. v 1.1 Δe29 / ClC-1 - / - In mice, there is a significant reduction in ventilation and minute ventilation. Finally, respiratory function is improved by Ca v 1.1 Δe29 / ClC-1- / - Moderately affected by amlodipine treatment in mice. Symbols, open circles, individual mice; bars and closed circles, mean ± SEM. Note: Untreated Ca v 1.1 Δe29 / ClC-1 - / - Mice do not survive to 20 weeks of age
[0179] Ca v 1.1 Δe29 / ClC-1 - / - The effect of amlodipine in improving muscle function in mice was investigated. As shown in Figure 22, Ca v 1.1 Δe29 / ClC-1 - / - EDL isolated from mice was stained with untreated ClC-1 - / - Muscle function is similar to that of single mice. Figure 22A shows representative specific force traces evoked by 150 Hz (500 ms) tetanic (right) stimulation of isolated EDL muscles from 20-week-old mice. Figure 22B shows the average tetanic force generated during 500 ms, 150 Hz tetanic stimulation in isolated EDL muscles from 20-week-old mice. Figure 22C shows plots of the average stimulation frequency dependence of specific force generation from isolated EDL muscles at 20 weeks of age in the indicated genotypes and treatment groups. At 20 weeks of age, there is no significant effect on EDL muscle function and muscle force generation that could be due to amlodipine treatment. Force generation at 150 Hz and Ca v 1.1 Δe29 / ClC-1 - / - Frequency-dependent protocol reduction in mice is associated with ClC-1 - / - This parallels the lack of force seen in single mice. Symbols, filled circles, mean±SEM.
[0180] Ca v 1.1 Δe29 / ClC-1 - / - The effect of amlodipine in improving muscle function in diaphragm strips isolated from mice was also investigated. As shown in Figure 23, amlodipine treatment significantly improved muscle function in the amlodipine-treated Ca diaphragm strips, which had a reduction in force production compared to the WT diaphragm. v 1.1 Δe29 / ClC-1- / - Improves muscle function in isolated diaphragm strips from mice. Figure 23A shows representative specific force traces evoked by 150 Hz (500 ms) tetanic (right) stimulation of diaphragm strips isolated from 20-week-old mice. Figure 23B shows the average tetanic force generated during 500 ms, 150 Hz tetanic stimulation in diaphragm strips isolated from 20-week-old mice. Figure 23C shows plots of the average stimulation frequency dependence of specific force generation from isolated diaphragm strips at 20 weeks of age in the indicated genotypes and treatment groups. At 20 weeks of age, there is no significant effect on diaphragm muscle function and muscle force generation that could be due to amlodipine treatment. Force generation at 150 Hz and Ca v 1.1 Δe29 / ClC-1 - / - Frequency-dependent protocol reduction in mice is associated with ClC-1 - / - This is comparable to the lack of force seen in single mice. 1- / - Compared to mice alone, treated with Ca v 1.1 Δe29 / ClC-1 - / - Frequency, ventilation, and minute ventilation in mice did not show significant differences. It is reasonable to expect similar values for diaphragm muscle function from in vitro contraction experiments. Symbols, filled circles, mean ± SEM.
[0181] Ca v 1.1 Δe29 / ClC-1 - / - The effect of amlodipine in improving transient weakness in mice was investigated. As shown in Figure 24B, Ca v 1.1 Δe29 9-AC exacerbates the transient weakness of myotonic muscles and is alleviated by amlodipine. Figure 24A shows the effect of 100 mM 9-AC added to the bath (before treatment) on 20-week WT and Ca v 1.1 Δe29 Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 s apart, recorded ex vivo from isolated EDLs from mice. When muscle tone is pharmacologically induced, Ca is increased compared to WT. v 1.1 Δe29There is a significant decrease in force production in the EDL, which is due to myotonic Ca v 1.1 Δe29 This is due to a more severe transient weakness in the tissue. v 1.1 Δe29 (n=5), and Ca v 1.1 Δe29 Plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from one mouse in +9-AC (n=5). Additionally, average data captured in a representative trace reveals myotonic Ca v 1.1 Δe29 There is significant transient weakness in the EDL. In the absence of muscle tone, there is only mild transient weakness seen in the myotonic WT EDL, and no muscle tone, compared with WT or Ca v 1.1 Δe29 No transient weakness of the EDL was observed. Figure 24C shows the results of 20-week WT and Ca2+-treated rats in the presence of 100 mM 9-AC and 10 mM amlodipine (Figure 24C) added to the bath. v 1.1 Δe29 Figure 24D shows representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 s apart, recorded ex vivo from isolated EDLs from mice. v 1.1 Δe29 +10 mM amlodipine (n=5), and Ca v 1.1 Δe29 Figure 24 shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from the EDL of +9-AC + 10 mM amlodipine (n=5). The dashed line in Figure 24D represents the average data presented in Figure 24B as a pre-treatment reference. Both the representative traces and the average data show that myotonic Ca v 1.1 Δe29There was an improvement in the transient weakness of the EDL with bath treatment with 10 mm amlodipine. The initial decline in force production was improved, and myotonic Ca v 1.1 Δe29 Significant improvement in transient weakness during recovery from EDL weakness. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used.
[0182] Next, we investigated the effect of amlodipine in improving transient weakness of myotonic muscles. As shown in Figure 25, Ca v 1.1 Δe29 9-AC exacerbates the transient weakness of myotonic muscles and is alleviated by diltiazem. Figure 25A shows the effect of diltiazem on the transient weakness of 20-week WT and Ca-treated rats in the presence of 100 mM 9-AC added to the bath (before treatment). v 1.1 Δe29 Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from mice. v 1.1 Δe29 (n=5), and Ca v 1.1 Δe29 Figure 25C shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from 20 week WT and Ca + 9-AC (n=5) mice in the presence of 100 mM 9-AC and 10 mM diltiazem added to the bath (Figure 25C). v 1.1 Δe29 Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from mice. v 1.1 Δe29 +10 mM diltiazem (n=5), and Ca v 1.1 Δe29Figure 25 shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from the EDL in +9-AC + 10 mM diltiazem (n=5). The dashed line in (Figure 25D) represents the average data presented in (Figure 25B) as a pre-treatment reference. Overall, myotonic Ca in the presence of diltiazem in the bath v 1.1 Δe29 There is a significant improvement in transient weakness of the EDL. Diltiazem improves the initial drop in force production between the first and second tetanus and the overall recovery from transient weakness. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used.
[0183] This example provides further investigation of the effect of nifedipine on muscle function. As shown in FIG. v 1.1 Δe29 9-AC exacerbates the transient weakness of myotonic muscles and is alleviated by nifedipine. Figure 26A shows the effect of 100 mM 9-AC added to the bath (before treatment) on 20-week WT and Ca v 1.1 Δe29 Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from EDLs isolated from mice. v 1.1 Δe29 (n=5), and Ca v 1.1 Δe29 Figure 26C shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from 20 week WT and Ca + 9-AC (n=5) mice in the presence of 100 mM 9-AC and 10 mM nifedipine (Figure 26C) added to the bath. v 1.1 Δe29Representative normalized force traces of the first 15 tetanic contractions (100 Hz, 500 ms) spaced 4 seconds apart recorded ex vivo from isolated EDLs from mice. v 1.1 Δe29 + 10 mM nifedipine (n=5), and Ca v 1.1 Δe29 Figure 26 shows plots of average peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 seconds apart from the EDL in +9-AC + 10 mM nifedipine (n=5). The dashed line in Figure 26D represents the average data presented in Figure 26B as a pre-treatment reference. Overall, myotonic Ca2+ nifedipine in the bath was significantly increased in the presence of nifedipine. v 1.1 Δe29 There is a significant improvement in transient weakness of the EDL. Nifedipine improves the initial drop in force production between the first and second tetanus and the overall recovery from transient weakness. Symbols, filled circles, mean ± SEM. Note: When possible, the contralateral EDL was used.
[0184] Figures 27A and 27B show that transient weakness in WT and Ca v 1.1 Δe29 FIG. 27A is a series of graphs showing that WT and Ca v 1.1 Δe29 Representative traces of the first 15 tetanic contractions (150 Hz, 500 ms) spaced 4 seconds apart in the EDL muscle are shown in Figure 27B. v 1.1 Δe29 Figure 1 shows plots of mean peak tetanic EDL force normalized to the initial stimulus evoked by 44 subsequent 100 Hz, 500 ms tetanic stimuli spaced 4 s apart from EDLs isolated from mice. v 1.1 Δe29 This was a control experiment to test whether the absence of drug in the bath had any effect on the transient relaxation. v 1.1Δe29 No differences were observed between the EDL and non-EDL. Symbols, filled circles, mean ± SEM.
[0185] 28A, 28B, 28C, and 28D show Ca v 1.1 Δe29 significantly worsened myotonia, and amlodipine significantly worsened myotonic WT and Ca v 1.1 Δe29 Figures 28A and 28B (left) are a series of graphs showing that 20-week WT and Ca2+ reduced muscle tone in the EDL of mice in the absence (pre-treatment) (Figure 28A, left) and in the presence of 10 mM amlodipine added to the bath (Figure 28B, left). v 1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) separated by 3 min, recorded ex vivo from EDL isolated from mice. The dashed line represents the cumulative force production. Figures 28A and 28B (right) show plots of the average integral normalized against the specific force shown in the respective left panels. In the absence of 9AC in the bath, WT and Ca v 1.1 Δe29 A) the EDLs of 20-week WT and Ca-treated mice were incubated with 100 mM 9-AC and in the absence (before treatment) (Fig. 28C, left) and in the presence of 10 mM amlodipine added to the bath (Fig. 28D, left). v 1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) recorded ex vivo from isolated EDLs from mice, separated by 3 min. The dashed line represents the cumulative force production. Figures 28C and 28D (right) show plots of the mean integral normalized to the specific force shown in the respective left panels. From the untreated experiment in Figure 28C, there was a significant increase in Ca compared to WT EDL. v 1.1 Δe29 Representative traces show that in the presence of 9AC, Ca v 1.1 Δe29This is further illustrated by the average data on the right side of Figure 28C. In Figure 28D, when amlodipine was present in the bath, Ca v 1.1 Δe29 The mean data on the right side of Figure 28D show that WT and Ca v 1.1 Δe29 There is a significant difference between the first tetanus between the mice and the control mice, but subsequent tetanus shows no difference in muscle tone with amlodipine treatment. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used.
[0186] 29A, 29B, 29C, and 29D show Ca v 1.1 Δe29 significantly worsened muscle tone, and diltiazem reduced myotonic WT and Ca v 1.1 Δe29 Figures 29A and 29B (left) are a series of graphs showing that 20-week WT and Ca2+ reduced muscle tone in the EDL of mice in the absence (pre-treatment) (Figure 29A, left) and in the presence of 10 mM diltiazem added to the bath (Figure 29B, left). v 1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from EDLs isolated from 20-week-old WT and Ca mice. The dashed line represents the cumulative force production. Figures 29A and 29B (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 29C and 29D (left) show the results of the analysis of EDLs of 20-week-old WT and Ca mice incubated with 100 mM 9-AC in the absence (pre-treatment) of diltiazem (Figure 29C, left) and in the presence of 10 mM diltiazem added to the bath (Figure 29D, left). v 1.1 Δe29Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from isolated EDLs from mice are shown. The dashed lines represent the cumulative force production. Figures 29C and 29D, right, show plots of the mean integral normalized to the specific force shown in the respective left panels. In Figure 29D, when diltiazem was present in the bath, the force was greater in WT and Ca mice. v 1.1 Δe29 The mean data on the right side of Figure 29D show that in the presence of diltiazem, muscle tone is reduced in both WT and CaEDL. v 1.1 Δe29 There was a significant difference in tetanus between WT and Ca v 1.1 Δe29 For both, muscle tone is significantly reduced when diltiazem is present in the bath, as compared to FIG. 29C (right) for all three tetanic contractions. Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used.
[0187] 30A, 30B, 30C, and 30D show Ca v 1.1 Δe29 significantly worsened muscle tone, and nifedipine significantly worsened myotonic WT and Ca v 1.1 Δe29 30A and 30B (left) show that 20-week WT and Ca2+ reduced muscle tone in the EDL of mice in the absence (pre-treatment) (FIG. 30A, left) and in the presence of 75 nM nifedipine added to the bath (FIG. 30B, left). v 1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) 3 min apart recorded ex vivo from isolated EDLs from mice. The dashed line represents the cumulative force production. Figures 30A and 30B (right) show plots of the average integral normalized to the specific force shown in the respective left panels. Figures 30C and 30D (left) show the results of the normalization of force from 20-week WT and Ca mice incubated with 100 mM 9-AC in the absence (pre-treatment) of nifedipine (Figure 30C, left) and in the presence of 75 nM nifedipine added to the bath (Figure 30D, left). v1.1 Δe29 Representative normalized force traces of the first of three tetanic contractions (100 Hz, 500 ms) recorded ex vivo from isolated EDLs from mice, separated by 3 min. The dashed line represents the cumulative force production. Figures 30C and 30D (right) show plots of the mean integral normalized against the specific force shown in the respective left panels. In Figure 30D, when nifedipine was present in the bath, Ca v 1.1 Δe29 The mean data on the right side of Figure 30D show that WT and Ca v 1.1 Δe29 There was a significant difference in muscle tone between the two groups. る Symbols, open circles, individual mice; bars, mean and SEM. Note: When possible, the contralateral EDL was used.
[0188] 31A, 31B, and 31C show LR and Mbnl1 - / - FIG. 31A is a series of graphs showing that the combination of HSA with verapamil was synthetically lethal, resulting in significant reductions in survival and body weight, and increased time to righting. Verapamil treatment significantly improved survival and time to righting. LR / Mbnl1 + / + + Vehicle, HSA LR / Mbnl1 + / + +100mg / kg / day verapamil, HSA LR / Mbnl - / - + Vehicle and HSA LR / Mbnl1 - / - Results of Kaplan-Meier survival analysis of +100 mg / kg / day verapamil. LR / Mbnl1 - / - Mice had a significantly reduced life span. Treatment with 100 mg / kg / day of verapamil significantly improved survival. Figure 31B shows the average weekly weight change. Untreated HSA LR / Mbnl1 - / - Mice were treated with naïve HSA LR / Mbnl1 + / + The mice showed a significant weight loss from the weight loss. LR / Mbnl1- / - The weight of the mice was similar to that of untreated mice, but the weight of the mice increased as the mice aged. LR / Mbnl1 + / + + Vehicle, HSA LR / Mbnl1 + / + +100mg / kg / day verapamil, HSA LR / Mbnl - / - + Vehicle and HSA LR / Mbnl1 - / - Weekly righting time analysis of +100 mg / kg / day verapamil. Untreated HSA LR / Mbnl1 - / - Mice have a significantly longer righting reflex time. As they age, the time to right increases until they are unable to right themselves, which is when the mice take more than 60 seconds to right themselves. HSA LR / Mbnl1 - / - Treatment with 100 mg / kg / day verapamil in mice significantly improves righting latency. Symbols, filled circles, and errors, mean±SEM.
[0189] 32A, 32B, and 32C show LR and Mbnl1 - / - FIG. 32A is a series of graphs showing that the combination of HSA with 1,2-dichlorophenyl 2-propanediol was synthetically lethal, resulting in significant reductions in survival and body weight, and increased time to righting. Amlodipine treatment significantly improved survival and time to righting. LR / Mbnl1 + / + + Vehicle, HSA LR / Mbnl1 + / + +100mg / kg / day amlodipine, HSA LR / Mbnl - / - + Vehicle and HSA LR / Mbnl1 - / - Results of Kaplan-Meier survival analysis of +100 mg / kg / day amlodipine. Untreated HSA LR / Mbnl1 - / - Mice had a significantly reduced life span. Treatment with 100 mg / kg / day of amlodipine significantly improved survival. Figure 32B shows the average weekly weight change. Untreated HSA LR / Mbnl1 - / - Mice were treated with naïve HSA LR / Mbnl1 + / + The mice showed a significant weight loss. Amlodipine treatment reduced HSA LR / Mbnl1 - / - The weight of the mice was similar to that of untreated mice, but the weight of the mice increased as the mice aged. LR / Mbnl1 + / + + Vehicle, HSA LR / Mbnl1 + / + +100mg / kg / day amlodipine, HSA LR / Mbnl - / - + Vehicle and HSA LR / Mbnl1 - / - Weekly righting time analysis of +100 mg / kg / day amlodipine. Untreated HSA LR / Mbnl1 - / - Mice have a significantly longer righting reflex time. As they age, the time to right increases until they are unable to right themselves, which is when the mice take more than 60 seconds to right themselves. HSA LR / Mbnl1 - / - Treatment with 100 mg / kg / day amlodipine in mice significantly improves righting time. Symbols, filled circles, and errors, mean ± SEM. Statistical analysis: One-way or two-way ANOVA with multiple comparisons was used to test for significant differences between each of the groups tested. For survival, each group was compared with the Kaplan-Meier log-rank test of each other group. Please note that for asterisks in all figures, p values were used as follows: *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
[0190] The foregoing examples and descriptions of preferred embodiments should be understood as illustrative rather than limiting the present disclosure as defined by the claims. As will be readily understood, numerous variations and combinations of the above features may be utilized without departing from the present disclosure as set forth in the claims. Such variations are not to be considered as departing from the scope of the present disclosure, and all such variations are intended to be included within the scope of the following claims. All references cited herein are incorporated by reference in their entirety.
Claims
1. 1. A method of treating a myotonic disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent that inhibits calcium channels in the subject's cells.
2. 2. The method of claim 1, wherein the calcium channel is a Cav1.1 calcium channel.
3. 2. The method of any one of the preceding claims, wherein the drug is selected from the group consisting of verapamil, amlodipine, diltiazem, nifedipine, stereoisomers thereof, derivatives thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
4. 10. The method of any one of the preceding claims, wherein the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia.
5. 5. The method of claim 4, wherein the myotonic dystrophy is myotonic dystrophy type 1 (DM1) or myotonic dystrophy type 2 (DM2).
6. 5. The method of claim 4, wherein the myotonic dystrophy is associated with aberrant alternative splicing of RNA encoding the CIC-1 chloride channel or the Cav1.1 calcium channel.
7. 5. The method of claim 4, wherein the congenital myotonia is Becker type or Thomsen type congenital myotonia.
8. 5. The method of claim 4, wherein the sodium channel myotonia is paramyotonia congenita, hyperkalemic periodic paralysis, or potassium-induced myotonia.
9. 10. The method of any one of the preceding claims, wherein the subject has one or more mutations in SCN4A, Clcn1, or Cac1ns, or has alternative splice isoforms of Clcn1 or Cac1ns.
10. 10. The method of any one of the preceding claims, wherein the subject is a mammal.
11. 10. The method of any one of the preceding claims, wherein the subject is a human.
12. 13. The method of any one of the preceding claims, wherein the agent is administered to the subject in one or more doses of about 0.01 to about 100 mg / kg body weight of the subject.
13. 13. The method of any one of the preceding claims, wherein the agent is administered in one or more doses of about 1 to about 50 mg / kg body weight of the subject.
14. 13. The method of any one of the preceding claims, wherein the agent is administered in one or more doses of about 8 to about 16 mg / kg body weight of the subject.
15. 15. The method of any one of claims 12-14, wherein the one or more doses of the agent are administered at least once a day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, or 4 weeks.
16. 13. The method of any one of the preceding claims, wherein the agent is administered to the subject intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, sublingually, sustained release, controlled release, delayed release, or as a suppository.
17. 13. The method of any one of the preceding claims, further comprising administering to the subject an additional therapeutic agent or therapy.
18. 18. The method of claim 17, wherein the additional therapeutic agent is selected from the group consisting of ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, lamotrigine, and combinations thereof.
19. 10. The method of any one of the preceding claims, wherein said treatment results in a therapeutic effect selected from the group consisting of reduced muscle tone, reduced weight loss, improved survival, improved muscle function, improved righting reflex time, improved respiratory function, and improved diaphragm strength.
20. 10. The method of any one of the preceding claims, wherein said treatment results in at least a 50% improvement in muscle tone, weight loss, survival, muscle function, righting reflex time, respiratory function, or diaphragm strength compared to untreated subjects.
21. 2. Use of an agent that inhibits calcium channels (a calcium channel blocker) in the manufacture of a medicament for treating a myotonic disorder in a subject in need thereof.
22. 22. The use of claim 21, wherein the drug is selected from the group consisting of verapamil, amlodipine, diltiazem, nifedipine, stereoisomers thereof, derivatives thereof, or pharma- ceutically acceptable salts thereof, and combinations thereof.
23. 23. The use according to claim 21 or 22, wherein the calcium channel is a Cav1.1 calcium channel.
24. The use according to any one of claims 21 to 23, wherein the myotonic disorder is myotonic dystrophy, autosomal dominant or recessive congenital myotonia, or sodium channel myotonia.
25. 1. A pharmaceutical composition comprising: (a) a calcium channel blocker selected from the group consisting of verapamil, amlodipine, diltiazem, nifedipine, and combinations thereof; and (b) one or more agents selected from the group consisting of ranolazine mexiletine, flecainide, tocainide, phenytoin, carbamazepine, and lamotrigine.
26. 26. A kit comprising the pharmaceutical composition of claim 25.
